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Interactions between molecules are the basis of cellular function. In disease, these tightly 
regulated systems are often disturbed. Parkinson’s disease (PD) is recognized by protein 
aggregates in the brain of erroneously interacting molecules, directly linking the clinical picture 
to the molecular mechanisms. The currently incomplete understanding of the mechanisms 
behind PD pathogenesis impedes the development of disease-modifying treatment and new 
targets are needed since today’s dopaminergic treatment does not fully alleviate the symptoms. 
G protein-coupled receptors (GPCRs) are a wide group of transmembrane receptors usually 
targeted by drugs due to their ability to convey extracellular information into definite cellular 
responses. This Thesis focuses on protein interactions, from cellular models of a Parkinson-
linked GPCR, GPR37, to detection of nanoaggregates in serum from PD patients as a sign of 
disease.  
The main findings relate to the interactome of GPR37 as a factor regulating cell survival. 
GPR37 has been suggested to accumulate and cause dopaminergic cell death in PD when 
improperly folded but is able to elicit cytoprotective function when correctly matured and 
trafficked to the cell surface. We report that GPR37 interaction with ganglioside GM1-enriched 
lipid rafts and a proposed ligand prosaposin affects trafficking of GPR37 to the plasma 
membrane. Since the role of lipids in PD pathogenesis is increasingly acknowledged and GM1 
has been suggested to slow down PD progression in clinical studies, we further studied the 
mechanism of the GPR37-GM1 interaction. We propose that exogenous GM1 treatment 
increase cellular resistance to a neurotoxin partly through a GPR37-dependent mechanism. 
This suggests yet another molecular mechanism of GM1 cytoprotection. Moreover, GPR37 has 
been suggested to be a modulator of dopaminergic transmission why we investigated the 
proposed interaction with dopamine D2 receptor (D2R) and GPR37 in live cells. The levels of 
heterodimerization where generally low in our cellular system. However, it could be 
augmented both by chaperone treatment, inducing trafficking of GPR37, and by clinically used 
dopamine agonist treatment. Shifting the heterodimerization level of GPCRs is known to alter 
molecular response. Therefore, the physiological outcome of this interaction needs to 
deciphered to understand effects and side effects of dopamine agonist treatment. 
We also investigate improper protein interactions as a potential biomarker in serum from PD 
patients by detection of β-sheet enriched nanoaggregates. We report a higher detected 
frequency of nanoamyloids in patients compared to healthy controls and a bimodal distribution 
of amyloid size in serum. However, the frequency of nanoamyloids did not correlate robustly 
with neither disease progression or disease symptoms. Potentially this is due to heterogeneity, 
both clinical and molecular, in the disease. This emphasizes the need of understanding the 





LIST OF SCIENTIFIC PAPERS 
I. Gregorsson Lundius E, Vukojević V, Hertz E, Stroth N, Cederlund A, Hiraiwa 
M, Terenius L, Svenningsson P. GPR37 Protein Trafficking to the Plasma 
Membrane Regulated by Prosaposin and GM1 Gangliosides Promotes Cell 
Viability.  
Journal of Biological Chemistry (2014) 289(8), 4660-73 
 
II. Hertz E, Terenius L, Vukojević V, Svenningsson P. GPR37 and GPR37L1 
Differently Interact With Dopamine 2 Receptors in Live Cells. 
Neuropharmacology (2019) 152, 51-57 
 
III. Hertz E., Saarinen M., Svenningsson P. GM1 is Cytoprotective in GPR37-
Expressing Cells and Down Regulates Signaling.  
Manuscript 
 
IV. Hertz E.*, Tiiman A*, Terenius L, Vukojević V, Svenningsson P. Increased 




ADDITIONAL PUBLICATIONS BY THE AUTHOR 
 Blokzijl A, Nong R, Darmanis S, Hertz E, Landegren U, Kamali-
Moghaddam M. Protein Biomarker Validation via Proximity Ligation 
Assays. 
Biochim Biophys Acta. (2014) 1844(5):933-9. 
 
Blokzijl A, Zieba A, Hust M, Schirrmann T, Helmsing S, Grannas K, Hertz 
E, Moren A, Chen L, Söderberg O, Moustakas A, Dübel S, Landegren U. 
Single Chain Antibodies as Tools to Study Transforming Growth factor-β-
Regulated SMAD Proteins in Proximity Ligation-Based Pharmacological 
Screens. 
Mol Cell Proteomics. (2016) 15(6):1848-56 
 
Yang J, Hertz E, Zhang X, Leinartaité L, Gregorsson Lundius E, Li J,  
Svenningsson P. Overexpression of α-Synuclein Simultaneously Increases 
Glutamate NMDA Receptor Phosphorylation and Reduces 
Glucocerebrosidase Activity.  
Neuroscience Letters (2016) 611, 51-8 
 
 Hertz E, Thörnqvist M, Holmberg B, Machaczka M, Sidransky E, 
Svenningsson P. First Clinicogenetic Description of Parkinson's Disease 
Related to GBA Mutation S107L. 
Movement Disorders Clinical Practise (2019) 6(3), 254-258 
 
 Markaki I, Bergström S, Tsitsi P, Remnestål J, Månberg A, Hertz E, 
Paslawski W, Sorjonen K, Uhlen M, Mangone G, Carvalho S, Rascol O,  
Meissner W.G, Magnin E, Wüllner U, Corvol JC, Nilsson P, Svenningsson 
P, AETIONOMY study group. Cerebrospinal Fluid Protein Markers of 
Cognition in Early Parkinson's Disease.  
Movement Disorders, under revision 
CONTENTS 
1 Introduction ............................................................................................................ 1 
1.1 G protein-coupled receptors (GPCRs) ............................................................. 1 
1.1.1 GPCR-mediated signaling cascades ..................................................... 2 
1.1.2 GPCR interactions .............................................................................. 3 
1.1.3 Dopamine receptors ............................................................................ 4 
1.1.4 GPR37 ............................................................................................... 6 
1.1.5 GPR37L1 ........................................................................................... 8 
1.2 Parkinson’s disease ........................................................................................ 9 
1.2.1 The clinical picture ............................................................................. 9 
1.2.2 Overview of the dopaminergic system and structures important in 
PD .................................................................................................... 10 
1.3 Molecular mechanisms in Parkinson’s disease .............................................. 11 
1.3.1 α-synuclein ....................................................................................... 11 
1.3.2 Dysfunctional protein folding and aggregation................................... 12 
1.3.3 Protein degradation ........................................................................... 13 
1.3.4 Lipids in neurodegeneration .............................................................. 14 
1.3.5 Mitochondria dysfunction and oxidative stress................................... 15 
1.3.6 Summary of pathogenic mechanisms................................................. 15 
1.4 Treatment of Parkinson’s disease .................................................................. 16 
1.4.1 Treatment today ................................................................................ 16 
1.4.2 Potential future treatment .................................................................. 17 
1.5 Summary ..................................................................................................... 18 
2 Aims ..................................................................................................................... 19 
3 Methodological Considerations ............................................................................. 20 
3.1 Fluorescence correlation and cross-correlation spectroscopy (FCS/FCCS) ..... 20 
3.1.1 Principles ......................................................................................... 20 
3.1.2 Fluorescence cross-correlation spectroscopy (FCCS) ......................... 22 
3.1.3 Applications ..................................................................................... 24 
3.1.4 Methodological considerations .......................................................... 24 
3.2 Cell toxicity assays....................................................................................... 25 
3.3 Cell signaling assays .................................................................................... 26 
3.4 Clinical evaluation of parkinson’s disease ..................................................... 27 
3.4.1 Parkinson symptoms ......................................................................... 27 
3.4.2 Disease severity ................................................................................ 27 
3.4.3 Non-motor symptoms scales ............................................................. 28 
3.4.4 Cognitive decline .............................................................................. 28 
3.4.5 Depression ....................................................................................... 29 
4 Results and Discussion .......................................................................................... 30 
4.1 Interactions affecting trafficking of GPR37 (Paper I and II) ........................... 30 
4.2 GPR37 interaction with GM1 (Paper I and III) .............................................. 34 
4.3 Detection of nanoamyloids in PD patients (Paper IV) .................................... 37 
 
 
5 Conclusions and Outlook ...................................................................................... 41 
6 Summary of Papers ............................................................................................... 42 
7 Acknowledgements .............................................................................................. 44 
8 References ............................................................................................................ 46 
 
  
LIST OF ABBREVIATIONS 
α-syn α-synuclein 
A2AR adenosine receptor 2A 
AC adenylyl cyclase 
AD Alzheimer’s disease 
ALP autophagy-lysosome pathway 
ATP adenosine 5’ triphosphate 
BB bombesin 
cAMP cyclic adenosine monophosphate 
CNS central nervous system 
COMT catechol-O-methyltranseferase 
CSF cerebrospinal fluid 
CtxB cholera toxin β-subunit 
D2R dopamine receptor 2 
D2R dopamine receptor 2-long 
D2RS dopamine receptor 2-short 
DAT dopamine transporter 
eGFP enhanced green fluorescent protein 
ER endoplamatic reticulum 
ET endothelin 
FCS fluorescence correlation spectroscopy 
FCCS fluorescence cross-correlation spectroscopy 
FDA Food and Drug Administration 
FRET Förster/fluorescence resonance energy transfer 
 fSEO frequency of single event occurance 
GPCR G protein-coupled receptor 
GCase glucocerebrosidase 
G protein guanine nucleotide-binding protein 
GRK G protein-coupled receptor kinase 
H&Y Hoehn and Yahr 
HA head activator 
 
 
HTRF homogeneous time-resolved fluorescence 
iPSC induced pluripotent stem cells 
IP3 inositol triphosphate 
ICD impulse control disorder 
iPSC induced pluripotent stem cells 
KO knock out 
LB Lewy bodies 
MAO-B monoamine oxidase B 
MDS Movement Disorder Society 
MEM maximum entropy method 
MPP+ 1-methyl-4-phenylpyridinium 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NfL neurofilament light 
NMS non-motor symptoms 
NPD1 neuroprotection D1 
OVE observation volume element 
PD Parkinson’s disease 
PKA protein kinase A 
PLC phospholipase C 
PSAP prosaposin 
RCCA relative cross-correlation amplitude 
ROS reactive oxygen species 
RTK receptor tyrosine kinase 
SBD sfingolipid binding domain 
SN substantia nigra 
SNpc substantia nigra pars compacta 
ThT thioflavin T 
UPDRS unified Parkinson’s disease rating scale 
UPR unfolded protein response 
UPS ubiquitin-proteosome system 





Proteins, the main effectors of the cell, act in complex molecular networks that are 
interdependent of each other. After sequencing the human genome and mapping all proteins to 
specific tissues, dynamic interactions between molecules add a new layer of complexity. To 
map the protein interactome and comprehend the outcome of interactions is a major scope of 
today’s biological research1. Dysregulation in the spatial and temporal control of a protein’s 
interactome may lead to, among other problems, protein aggregation and disturbed signaling 
cascades. This Thesis focuses on proteins linked to cell survival in Parkinson’s disease (PD), 
their interactions and relevance, from mechanism to clinical implications.  
PD is a common neurodegenerative disorder marked by a progressive degeneration of 
dopaminergic neurons in the substantia nigra (SN) and accumulation of protein aggregates in 
the remaining neurons. The accompanying reduction of dopamine level in the striatum is 
associated with the motor deficits characteristic of PD. Present dopamine-replacing therapies 
bring symptomatic relief of motor symptoms. However, treatment of non-motor symptoms 
(NMS) is unsatisfactory, side-effects are disabling, and, most importantly, the treatment has no 
slowing effect on the underlying cell death. To date the events leading to dopaminergic 
degeneration are only partly elucidated. To understand the dysfunctional cellular and molecular 
mechanisms is key to develop future disease modifying treatments. 
1.1 G PROTEIN-COUPLED RECEPTORS (GPCRS) 
G protein-coupled receptors (GPCRs) are the largest group of cellular surface receptors in the 
human genome including at least 800 transmembrane receptors2. Based on sequence 
homology, members of this super-family are allotted into 5 classes; rhodopsin-like (class A), 
secretin-like (class B1), adhesion receptors (class B2), metabotropic glutamate-like (class C) 
and frizzled/taste2 receptors (class F)2,3,. Embedded in cellular membranes, GPCRs share a 7-
α-helical transmembrane domain structure with an extracellular amino-terminal domain and an 
intracellular carboxyl-terminal tail (Fig. 1A). They convey a myriad of extracellular 
information, transducing signals from photons to neurotransmitters, into elicit versatile cellular 
responses. They are often pictured as ideal targets for drugs due to their ability to specifically 
bind ligands and allosteric modulators and they are involved in almost all physiological 
processes. To date, about 1/3 of drugs approved by Food and Drug Administration (FDA) target 
a GPCR, underscoring the enormous role that GPCRs have on human health and disease4. 
However, approximately 140 GPCRs, including GPR37 which is central in this Thesis, have 
still not been linked to an endogenous ligand and are therefore known as “orphan receptors”5. 
Little is known of the physiological effects of these receptors and they are therefore an 
unexploited source for future treatments. 
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1.1.1 GPCR-mediated signaling cascades 
Key in flexibility of GPCR-mediated signaling is the wide span of intracellular interaction 
partners including guanine nucleotide-binding proteins (G proteins) and G protein independent 
scaffold proteins3. In the canonical pathway, signal transduction depends on receptor-mediated 
activation of heterotrimeric G proteins, composed of three subunits Gα, Gβ and Gγ6. The 
classification of G proteins depends on the Gα subunit which are divided into four classes; Gαs, 
Gαi/o, Gαq/11 and Gα12/13. Ligand-induced activation induces conformational changes of the 
receptor’s intracellular domains3. The coupling to G proteins trigger exchange of Gα-associated 
GDP to GTP which allows Gα to dissociate from Gβγ. Gα regulates key effectors which in turn 
generate second messengers capable of inducing distinct signaling cascades to propagate and 
amplify the signal. Gαs and Gαi/o regulates adenylyl cyclase (AC) activity which catalyzes 
adenosine triphosphate (ATP) to the second messenger cyclic adenosine monophosphate 
(cAMP). Gαq/11 modulate phospholipase C (PLC) to change inositol triphosphate (IP3) levels 
(Fig. 1B). IP3 in turn binds calcium pumps in the endoplasmic reticulum (ER) and thereby 
regulates intracellular Ca2+ levels. The G protein elicited signal is terminated through the 
intrinsic GTPase activity of Gα which hydrolyzes GTP to GDP allowing Gα to re-associate 
with Gβγ. Upon GPCR activation, the receptor’s cytoplasmic loops and C-terminal tail are 
phosphorylated by G protein coupled receptor kinases (GRK) and β-arrestin is recruited. This 
both blocks the binding heterotrimeric G proteins and initiate receptor internalization3. 
Thereby, the signaling pathway is terminated. In short, this is the traditional view of a GPCR-
mediated signaling event. 
 
Today’s understanding of GPCR activation and signaling is more detailed and complex. One 
GPCR can couple to different Gα-subunits depending on cellular situation, eliciting various 
downstream effects3. In addition, Gβγ subunit can induce separate signaling cascades. 
Furthermore, there are a number of G protein independent pathways where the β-arrestins are 
central. Historically, the β-arrestins are mainly studied as negative regulators of GPCR 
signaling. However, scaffolding β-arrestin can initiate a number separate signaling cascades, 
possibly due to the protein’s variability of active conformations6. These pathways are initially 
Figure 1. Schematic drawing of 
GPCR structure and function A) 
Structure of a GPCR with the 
extracellular N-terminal domain, 7 
trans-membrane helixes and an 
intracellular C-terminal tail.  
B) The initial steps in the 
canonical GPCR mediated 
signaling pathway where the 
different Gα subunits regulates 
key effectors, e.g., adenylyl 
cyclase (AC) and phospholipase C 
(PLC) which in turn generate 
second messengers.  
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separate from G protein dependent but include similar signaling cascades at a different time 
points7. This paradigm shift of GPCR-mediated signaling needs further studies to determine if 
the arrestin-dependents pathways are truly G protein-independent or requires initial G protein 
activation8. Furthermore, some GPCRs can simultaneously bind β-arrestin and G proteins9. 
Today it is evident that there is an intricate intertwining between the G protein dependent and 
G protein independent signaling pathways.  
This plethora of different signaling pathways has evolved into the concept of biased agonism. 
A GPCR should not be regarded as an on-off switch. Instead, it has multiple distinct active 
confirmations3. An agonist can preferentially stabilize specific confirmations and thereby 
trigger a subset of the existing intracellular cascades, or the full range. The biased receptor 
response can be induced by a ligand, splice form alterations in the receptor or by relative 
expression levels of the transducer proteins in different cell types7. Understanding how biased 
signaling is regulated could make it possible to tailor drugs that induce only the desirable 
pathway in the targeted cell type3.  
In addition to biased activation, GPCR’s signaling intensity are also regulated by expression 
levels, cellular localization and hence, cellular trafficking. When activated, the receptor is, in 
general, internalized as explained above. This process is followed either by recycling the 
receptor to the plasma membrane or degradation in the endosomal-lysosomal system. 
However, GPCRs are subjected to different fates after internalization, depending on arrestin 
recruitment and receptor phosphorylation. In addition, there is emerging evidence of 
intracellular GPCR signaling. GPCRs have been found on vesicles, mitochondria and the 
nuclear membrane10. Furthermore, endosomal internalization can lead to endosomal signaling, 
both G protein dependent and -arrestin dependent. This further increases the spatio-temporal 
regulation of GPCR signaling3, 11. 
1.1.2 GPCR interactions 
GPCRs can form protein complexes with other proteins. This adds an additional layer of 
complexity to signaling pathways since the interactions can allosterically modulate the 
signaling outcome12. Studies of this molecular integration developed in the 80s when the first 
reports of receptor-receptor interactions were published13. Dimerization was first recognized 
for GPCRs in the metabotropic-glutamate family and in 1998, heterodimerization was shown 
to be required for a functional GABAB receptor14. Today there is strong evidence also for 
dimerization in the rhodopsin-like and secretin-like receptor families12, 15. The interactions are 
well documented in heterologous systems but there are still difficulties to develop proper 
methods to study naïve systems. Homo- and heterodimers can modulate the pharmacological 
response and induce G protein coupling change from Gαs, to Gαi/o or towards β–arrestin 
signaling12,16. Since the dimers have different properties than the monomer, the number of 
possible ligand-receptor responses are increasing. The balance between monomers, dimers and 
larger oligomers determine the final cellular response which can be fine-tuned by shifting the 
equilibrium3. Levels of dimerization between GPCRs induced by pharmacological tools are 
studied in this Thesis.  
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GPCRs are embedded in a lipid membrane. The environment affects both lateral organization 
and allows for protein-lipid interactions17. The membrane’s properties including fluidity, 
composition, and thickness affects the arrangement of GPCRs. Assembly is, e.g, promoted if 
the hydrophobic portion of the GPCR is thicker than the plasma membrane since dimerization 
of two GPCRs then reduces the exposed hydrophobic area18. On a larger scale, the plasma 
membrane is compartmentalized into dynamic highly-ordered domains called lipid rafts, 
characterized by enrichment of cholesterol and sphingolipids including the ganglioside GM1. 
These hubs constrain essential signaling molecules, including GPCRs, into close proximity and 
thereby organize the bioactivity17. Apart from influencing GPCRs’ micro-environment, both 
cholesterol and sphingolipids can directly interact with GPCRs via typical binding motifs in 
transmembrane domains and extracellular loops19, 20. Membrane cholesterol can modulate 
GPCRs, e.g. adenosine receptor 2A (A2AR), by binding into the orthosteric binding pocket and 
hence act as a conventional ligand21, 22. In addition, just like protein-protein interactions, 
protein-lipid interactions can change preferred G protein-coupling23. Recently published 
simulation data of 28 GPCRs reveals specific lipid interactions for all GPCRs examined, 
although with a unique profile for each receptor24. This enforces the general feature that lipids 
intimately regulate GPCRs, either via direct interactions or lipid bilayer properties or possibly 
by a combination of both mechanisms21.  
In summary, GPCRs is a large and diverse group of transmembrane proteins which by 
remarkable specificity can orchestrate cellular response. The signaling cascades are 
functionally pleiotropic intricately regulated by trafficking, biased signaling and permanent or 
transient molecular interactions. GPCR regulation is hence not an on/off phenomenon but 
rather an integrated, cell-specific outcome. To understand and utilize this characteristic is 
desirable when designing drugs since the tissue and local environment specificity possibly can 
reduce side effects7. The following sections present the GPCRs relevant to PD that are 
investigated in this Thesis.  
1.1.3 Dopamine receptors 
The neurotransmitter dopamine controls a variety of physiological functions by acting on five 
GPCRs. In addition, dopamine receptors are well-established targets in clinical pharmacology 
treating PD as well as neuropsychiatric diseases. Due to their central role in human physiology 
the receptors are well characterized thus far.  
1.1.3.1 Structure and expression of dopamine receptors 
There are five closely related GPCRs exerting the physiological effects of dopamine, D1-D5, 
each one encoded by a separate gene. Depending on structural, pharmacological and 
biochemical properties, they are divided into D1-class receptors (D1 and D5) and D2-class 
receptors (D2, D3 and D4). D1-class receptors are expressed exclusively postsynaptically, 
couple to Gαs and their respective genes do not have introns. Class D2, on the opposite, couple 
to Gαi/o, D2 and D3 are localized both pre- and postsynaptically and the genes include introns
25. 
Due to the presence of introns, alternative splicing is feasible and have been described for all 
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D2-class receptors. The most studied example is an 87-base-pair exon in D2 which is 
alternatively spliced forming D2-short (D2RS) and D2-long (D2RL). D2RS is mainly 
expressed presynaptically and hence act as an autoreceptor while D2RL is mostly 
postsynaptic26. These variants are studied in this Thesis.  
Dopamine receptors are expressed broadly both in the central nervous system (CNS) as well as 
in the periphery. In the brain, D1 and D2 are vastly expressed in the nigrostriatal and 
mesolimbic areas including the striatum, the substantia nigra (SN), and ventral tegmental area 
(VTA), as well as in cortex, hippocampus and the amygdala. Expression of D3 is more 
restricted, with the highest levels in limbic areas and lower expression in striatum, SN and 
VTA. D4 and D5 are expressed in low levels in, e.g., frontal cortex, SN and thalamus for D4 
while D5 is expressed in the prefrontal cortex, premotor cortex as well as in SN and 
hippocampus25.  
1.1.3.2 Signaling pathways of dopamine receptors 
As stated above, principally D1-class receptors couple to Gαs
 whereas D2-class receptors 
mainly couple to Gαi in their canonical action on cAMP-mediated signaling. cAMP levels 
regulate protein kinase A (PKA) activity which in turn phosphorylates DARPP-32. DARPP-
32 is an integrator of neuronal transmission and has been extensively studied due to its pivotal 
role in dopamine signaling27. However, dopamine receptors are now known to fine-tune their 
response by activating a variety of signaling pathways28. These involve both alternative G 
protein coupling and non-G protein mediated mechanisms. Examples include; D1-class 
receptors regulating Ca2+ levels via Gαq coupling
28, β-arrestin-2 dependent late phase D2R 
signaling as well as transactivation of RTKs25. This more complex understanding of dopamine 
receptor transduction enables future progress in drug development aiming at post-receptor 
signaling targets. 
1.1.3.3 Molecular interactions of dopamine receptors 
Oligomerization of GPCRs is now widely established and dopamine receptors can form a wide 
range of homo- and heteroreceptors28, 29. These receptor interactions are suggested to modulate 
the response of dopamine activation which is important to disentangle therapeutic effects and 
side effects of dopaminergic treatments. In addition, due to heterodimerization non-
dopaminergic treatment strategies can potentially improve dopaminergic effects. One of the 
mostly studied interactions is between A2AR and D2R in the striatum. On the molecular level, 
the interaction shifts D2R signaling from Gαi towards β-arrestin signaling
30. In animal models 
of PD, A2AR antagonists decrease dyskinesia, a well-known side effect of PD treatment
31. 
Hence, modulation of A2AR can possibly fine-tune dopaminergic signaling and reduce 
disabling side effects. In another example D2R has been shown to interact with the NMDA 
receptor (NMDAR), a glutamate receptor, in striatal synapses32. Here D2R activation reduced 
NMDAR signaling in the indirect pathway, easing the brake on motor initiation (see Sect. 1.2.2 
for introduction to the dopaminergic networks). D2R has also been suggested to interact with 
GPR37 in vitro, an interaction further evaluated in this Thesis33, 34. Protein-protein interactions 
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reveal new potential treatment opportunities and expand the possibilities to modulate one of 
our most pharmacologically targeted GPCRs. 
1.1.3.4 Function of dopamine receptors in health and disease 
Since its discovery in the 1960s’ the dopaminergic system is one of the most studied 
neurotransmitter systems due to its involvement in fundamental human functions as well as 
common diseases such as PD, schizophrenia, and addiction. Dopamine signaling is essential in 
voluntary movement, reward, learning, and cognition25. In voluntary movement D1, D2 and 
D3 are primarily involved. D1 alters a pro-kinetic response, whereas the effect of D2 and D3 
activation is more complex due to the dual localization, both pre- and postsynaptic. D1 and D2 
are also involved in the evolutionary essential function feelings of reward. However, these are 
a major issue in drug abuse. Due to the critical roles of dopamine, dopamine receptors are 
common targets in clinical treatment25. PD is caused by a progressive loss of dopamine 
producing cells causing motor deficits. The standard care includes a precursor of dopamine, L-
DOPA, as well as dopamine receptor agonists to alleviate symptoms (please see Sect. 1.4.1). 
Furthermore, D2R antagonists were the first generation of antipsychotic medications. Those 
have been refined to reduce the accompanying motor function related side-effects, e.g., via 
activation of biased signaling35.  
1.1.4 GPR37 
G-protein-coupled receptor 37 (GPR37) is an orphan receptor with mainly unknown 
physiological function. In the literature the receptor has been extensively linked to PD 
pathogenesis due to its tendency to misfold in the ER causing protein aggregates. However, 
during recent years the receptor has been proposed to have neuroprotective functions if 
correctly folded. Due to its bidirectional role, it has been suggested as a potential 
pharmacological target in PD36.  
1.1.4.1 Structure and expression profile of GPR37 
GPR37 is a rhodopsine-like GPCR first recognized in 199737, 38. GPR37 and its closest relative 
GPR37L1 were identified through their homology with the endothelin (ETA and ETB) and 
bombesin (BB1, BB2 and BB3) receptors. Apart from its classical 7-transmembrane structure, 
GPR37 have a large extracellular N-terminal domain. This structure is similar to adhesion 
receptors where the extracellular domain is cleaved by autocatalysis39. Indeed, the N-terminal 
domain of GPR37, GPR37L1 and ETB are all cleaved but through metalloprotease activity
40-
42. The physiological effect of the cleavage is still elusive for GPR37. The receptor is almost 
exclusively expressed in the CNS, especially the corpus callosum and midbrain37, 38. 
Expression is mapped predominately to oligodendrocytes but also reported to specific neuronal 
populations in the hippocampus and the dopaminergic neurons in the SN43-45.  
1.1.4.2 Signaling pathways of GPR37 and suggested ligands 
In order to understand the characteristics of GPCR, a ligand which activates or deactivates the 
receptor is critical. GPR37 is still considered an orphan receptor and different dominating 
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downstream signaling cascades are reported. GPR37, although identified through close 
homology to endothelin and bombesin receptors, does not respond to either group of ligands. 
Several endogenous ligands have been suggested. First was head activator (HA), an 11 amino 
acid neuropeptide isolated from the Hydra. HA was reported to co-localize with the receptor 
and cause internalization. GPR37 was suggested to be Gi-coupled and induce Ca
2+ influx46. 
These results have been difficult to reproduce. Dunham et al. report lack of internalization, 
cAMP alteration and ERK phosphorylation and in a ligand screen, HA did not induce β-arrestin 
recruitment in GPR37-expressing cells33, 47. Furthermore, there is no evidence of an HA analog 
in the human genome and hence it is unlikely that HA is an endogenous ligand48.  
In 2013, prosaposin (PSAP, sphingolipid activator protein-1 or sulfated glycoprotein-1) was 
reported as the endogenous ligand for GPR37 and GPR37L149. Prosaposin is a well known 
neuroprotective and neurotropic protein when secreted extracellularly in its full length form50. 
Intracellularly, it is cleaved in the lysosome by cathepsin D into saposin A-D which all facilitate 
sphingolipid degradation51. Prosaposin, as well as the synthetic peptide of the neurotrophic 
sequence TX14(A), was reported to activate GPR37/GPR37L1 at nanomolar concentrations in 
a pertussis toxin-sensitive manner. This is specific for Gi-coupled receptors. Two separate 
groups have reported that PSAP confer protection against oxidative stress in 
GPR37/GPR37L1-dependent models49, 52. As presented in Paper I of this Thesis, PSAP has 
been detected to diffuse through the plasma membrane together with GPR37, indicative of a 
functional interaction. However, the pairing of GPR37/GPR37L1 and PSAP is still challenged 
as the changes detected in the signaling cascades are unusually small and not reproduced in 
other assays47, 48, 53. Moreover, REG4 which is a small proliferative protein has been suggested 
to enhance metastasis through GPR3754. Finally, neuroprotectin D1 (NPD1), a derivative of an 
omega-3 essential fatty acid member, was shown to increase intracellular Ca2+ in GPR37-
expressing macrophages. The same effect was seen with TX14(A) treatment and would 
indicate Gq-coupling of GPR37
55. NPD1 has previously been shown to have neuroprotective 
effects in ischemic as well as oxidative stress models possibly by downregulation of pro-
inflammatory and pro-apoptotic genes56. In order to circumvent the lack of a ligand, Zheng et 
al. elegantly generated a channelrhodopsin-GPR37 chimeric protein which when activated by 
light caused decreased cAMP levels and IP3-signaling concurrent with increased locomotion 
in mice57. As no consensus is achieved, GPR37 has regained its orphan receptor status and the 
initial steps of the induced signaling remains to be fully determined. 
1.1.4.3 Molecular interactions of GPR37 
In the absence of known ligands, the receptor’s interactome can aid advances in understanding 
the function of GPCRs. Molecular studies have identified numerous binding partners for 
GPR37 with various functional consequences. In a systematic protein-protein interaction study 
using a modified membrane yeast two hybrid screen assay for 48 human receptors, GPR37 was 
proposed to interact with several GPCRs including A2AR, D2R and the serotonin receptor, 5-
HT4D
34. The most studied interaction is between A2AR and GPR37 in the striatum where 




Thereby GPR37 directly affects adenosine signaling. In turn, this also alters A2AR’s modulatory 
functions, e.g. its regulation of D2R signaling described above. Through co-
immunoprecipitation GPR37 has also been shown to interact directly with D2R and dual 
expression led to enhanced plasma membrane expression, facilitating assessment of functional 
studies of classical GPCRs33. Furthermore, GPR37 has been reported to interact with the 
dopamine transporter (DAT) and thereby modulate dopamine reuptake59. The number of 
proposed interactions, indicative of physiological function, is increasing and suggests a role of 
GPR37 modifying dopamine transmission.  
1.1.4.4 GPR37 in health and disease 
The physiological function of GPR37 is still mainly unknown with multiple lines of current 
investigations. Linked to its expression in oligodendrocytes it has been proposed as a negative 
regulator of myelination and when knocked out (KO)60, mice exhibit increased susceptibility 
of demyelination61. GPR37 has also been proposed to regulate inflammation and enhance 
macrophage phagocytosis in mice after ischemic stroke. KO mice show augmented damage, 
both in size of ischemic injury and functional impairment55. However, GPR37 has gained most 
research attention due to its connection to PD pathogenesis. GPR37 is substrate of Parkin, an 
E3 ubiquitin ligase which should ubiquintinate misfolded proteins to induce degradation44. 
Mutations in Parkin is one of the most common causes in early onset PD, increasing the risk of 
accumulation of misfolded proteins62, 63. In Parkin-deficient mice, over expression of GPR37 
caused a progressive loss of catecholaminergic neurons. However, this effect was not seen in 
mice with a normal Parkin-gene64. In cellular studies, GPR37 is suggested to misfold and cause 
endoplasmic reticulum stress instead of being trafficked to the plasma membrane44. In human 
postmortem tissues from Parkin-deficient and sporadic PD cases, GPR37 is accumulated in the 
core of Lewy bodies (LB), the pathological hallmark of PD65. Furthermore, in an epigenome-
wide DNA methylation analysis GPR37 was the only gene differing in methylation level 
between monozygotic twins which are discordant for PD66. This indicates an acquired 
alternation possibly due to environmental factors. Taken together, GPR37 was suggested to 
easily misfold, aggregate and induce neurodegeneration. However in a cellular model, when 
GPR37 is expressed at lower, more physiological, levels and trafficked to the plasma 
membrane, the receptor was protective against neurotoxins67. The suggested ligands, PSAP 
and NPD1, are both known to exert neuroprotective functions49, 56. Hence, there is a hypothesis 
of a bidirectional role of GPR37 in neurodegeneration depending on cellular localization36. The 
physiological role, as well as GPR37’s role in neurodegeneration, still remains to be fully 
elucidated.  
1.1.5 GPR37L1 
GPR37L1, the receptor with 68% sequence similarity to GPR37, was identified a year after 
GPR3748, 68. Structure wise, GPR37L1 has a relatively large N-terminal domain similar to 
GPR37. As GPR37, GPR37L1 is highly expressed in the brain, especially the cerebellum, and 
the receptor is enriched in astrocytes. GPR37L1 is less studied than GPR37 and its 
physiological role is largely unknown. KO mice show precocious glia, Purkinje neuron 
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maturation and improved motor skills69. Furthermore, KO mice has an increased risk of 
seizures, like GPR37. Interestingly, a mutation in GPR37L1 has been found in a family with 
progressive myoclonus epilepsy70. Regarding ligand and signaling cascade, the studies 
proposing PSAP as the ligand for GPR37 claims that PSAP is also the endogenous ligand of 
GPR37L1 and that the receptor is Gi/o-coupled, possibly constituently active
70. There are also 
reports of Gs-coupling for GPR37L1
70. In several papers, GPR37L1 is studied in parallel with 
GPR37 in order to compare the results of those, relatively unknown receptors49, 52, 71.  
1.2 PARKINSON’S DISEASE 
1.2.1 The clinical picture 
The first description of Parkinson’s disease (PD) was six illustrative cases in An Essay on The 
Shaking Palsy by James Parkinson in 181772. PD is now known to be the second most common 
neurodegenerative disorder after Alzheimer’s disease (AD), affecting 2-3% of people over 65 
years of age73. Even though 200 years have passed since the first description the PD diagnosis 
is still clinical based on the features of parkinsonism defined as bradykinesia in combination 
with resting tremor and/or rigidity74. Gait impairment is common but is not an essential 
diagnostic sign today. In addition to progressive motor symptoms, patients experience a wide 
range of non-motor symptoms (NMS) including rapid eye movement (REM) sleep behavior 
disorder (RBD), loss of smell, obstipation, depression/anxiety and cognitive decline75. NMS 
often precede the onset of motor symptoms, disclosing disease progression before the 
characteristic motor symptoms are evident (Fig. 2). The combination of motor- and NMS 
unfortunately result in low quality of life for a large proportion of PD patients76, 77. The 
progression rate is highly individual and the combination of symptoms results in a 
heterogeneous disease where prognosis for the individual is difficult to predict78.  
 
The cause of the motor symptoms is a progressive loss of mostly dopaminergic neurons in the 
substantia nigra pars compacta (SNpc) causing striatal dopamine deficiency. Several other 
neurotransmitter systems are affected as the dopaminergic system receives modulatory input 
from serotonergic, cholinergic and glutamatergic neurons. Possibly, these other 
neurotransmitter networks are responsible for some of the non-motor features of PD73. In the 
Figure 2. Clinical symptoms associated with PD progression. Schematic of when common clinical 
symptoms usually occur. PD is diagnosed after the onset of motor symptoms. Patients may have experienced 
NMS years prior to diagnosis. 
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remaining neurons there are protein aggregates known as Lewy bodies (LB). The main 
constituent of LB is the presynaptic protein α-synuclein (α-syn) but they also include numerous 
other proteins, defect organelles and membrane lipids79,80. During disease progression, LB is 
suggested to spread in a topological predetermined pattern through the nervous system. 
According to the Braak neuropathological staging theory, inclusions are initially detected in 
the dorsal nucleus of the vagus nerve in the brain stem and in the olfactory bulb (stage 1). At 
stage 2 inclusion bodies are found in the medulla oblongata and at stage 3 the SN is reached 
which coincide with the onset of motor symptoms. In stage 4, LB pathology is spread to 
temporal cortex and when reaching the neocortex, stage 5 and 6, the cognitive decline can 
develop81.  
There are various diagnostic criteria of PD, all depending on the clinical signs of 
parkinsonism74. Studies indicate that up to 25% of PD diagnoses have another 
neuropathological disorder confirmed post mortem including atypical parkinsonism, vascular 
perturbations or AD-like pathology82. DaTSCAN is a single-photon emission computed 
tomography, visualizing striatal DAT. It has a high sensitivity for dopaminergic cell loss and 
can advice in uncertain cases of Parkinsonism but cannot distinguish between different forms78. 
The need of imaging methods or biomarkers are therefore immense to increase diagnostic 
precision. Despite intense research, there are no biomarkers in clinical use to date, neither for 
diagnosis, progression or treatment response83. Neurofilament light (NfL), a general marker of 
neurodegeneration, in cerebrospinal fluid (CSF) or blood can distinguish PD from atypical 
forms of Parkinsonism, were NfL is elevated84, 85. A recent study reports that blood NfL 
modestly correlate with clinical motor score and can be used as a marker of progression also in 
idiopathic PD86. This remains to be established especially since the PD cases included in the 
study were not pathologically confirmed. The precision of clinical PD diagnosis could be 
greatly improved by a biomarker. In addition, a biomarker could possible clarify etiological 
subtypes of PD giving a molecular understanding for the heterogeneity of the disease87. A new 
potential biomarker is presented in Paper IV of this Thesis. 
1.2.2 Overview of the dopaminergic system and structures important in PD 
The catecholamines are monoamine neurotransmittors derived from the amino acid tyrosine. 
In 1957, noradrenaline and dopamine was first suggested as specific neurotransmittors88, 89. A 
few years later the catecholaminergic system in the rat brain was mapped, initially localizing 
12 cell body groups (A1-A12)90. Later, five more groups were added (A13-A17). With 
improved biochemical techniques, our understanding of the anatomy of the catecholaminergic 
system advanced and the groups were separated into distinct groups of adrenaline, 
noradrenaline and dopamine producing neurons respectively. For humans, the majority of the 
dopaminergic neurons are located in the midbrain, in the SNpc (A9) and the VTA (A10)91.  
The most common projection site of the dopaminergic groups are the basal ganglia. The basal 
ganglia are a group of anatomically defined subcortical nuclei which integrate signals from 
different brain areas. They are key in controlling voluntary movement, learning and emotion. 
The main nuclei are SN, globus pallidus (GP), subthalamic nucleus (STN) and the striatum, 
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consisting of putamen, nucleus caudatus and nucleus accumbens. The dopaminergic neurons 
in the SNpc predominately project to the dorsal (‘motor’) striatum and neurons in VTA 
primarily project to the ventromedial (‘limbic’) striatum. This is an simplified view and there 
is an extensive overlap in projections from SN and VTA91, 92. The striatum is the main output 
nuclei, receiving input from cortex, thalamus and SNpc. 90% of the neurons in the striatum are 
GABAergic medium spiny neurons (MSN) projecting via two distinct pathways. The direct 
pathway directly innervates output nuclei whereas the indirect pathway relay via STN and GP 
externa. The MSN of the direct pathway express D1, increasing excitability in response to 
dopamine, whereas the indirect pathway express D2, decreasing excitability of the MSN. Due 
to this, the direct pathway is generally accepted to be pro-kinetic, while the indirect pathway is 
anti-kinetic and the balance between the two is essential for correct voluntary movement93.  
1.3 MOLECULAR MECHANISMS IN PARKINSON’S DISEASE 
The cause of dopaminergic cell death and accumulation of α-syn in PD is still elusive. 
Numerous cellular mechanisms are discussed as initiating and/or contributive to α-syn 
aggregation and disease progression. These include dysregulation of proteostasis, 
neuroinflammation, lipid alterations, mitochondrial damage, and axonal transport73. 
Historically, PD was perceived to mainly be caused by environmental factors. Now, a more 
multifaceted picture is accepted where genetic risk factors interact with the environmental 
factors94. A hereditary contribution, which can initiate the pathological cellular phenomena, is 
estimated in at least 30% of all cases95. Hence, there is likely to be several risk factors leading 
to cell death in each individual case. Therefore, a fundamental question today is if PD is one 
disease or the representative of a diverse set of biological processes leading to dopaminergic 
cell loss96. Below are the etiological theories relevant to the Thesis presented, beginning with 
presenting the essential protein α-syn.  
1.3.1 α-synuclein 
The central protein in PD pathogenesis is α-synuclein (α-syn) which misfolds into amyloid 
fibrils in LB. The link between PD and α-syn was first recognized in families with dominant 
autosomal PD where mutations where detected in SNCA, the gene encoding α-syn97. The same 
year, aggregated α-syn was acknowledged as the major component of LB79. α-syn is a 140 
amino acid small presynaptic protein which affects membrane curvature and synaptic 
homeostatis98. However, its full physiological mechanism is not completely understood. 
Monomeric α-syn is intrinsically disordered99-101 and exist in an equilibrium between an 
unfolded soluble state and a membrane-bound α-helical confirmation102, 103. Structurally the 
protein has three large domains. The central non amyloid component (NAC) domain is 
required, and sufficient, for aggregation104. Both increased levels of α-syn, induced by gene 
duplications or decreased degradation, and specific alterations, such as SNCA point mutations 
or posttranslational phosphorylation, increase the propensity to aggregate102,105. The misfolding 
process includes both metastable on-pathway oligomers, transforming into highly organized β-
sheet structured fibrils, and non-fibrillary off-pathway species98. The debate whether oligomers 
or fibrils are more toxic is still ongoing98, 106, 107 and since the oligomeric species are transient 
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by nature, they are difficult to study in vivo. These aggregates impair mitochondrial function, 
protein degradation and affects biological lipid bilayers which in turn is thought to cause 
neurodegeneration73. Even if there is strong evidence of α-syn’s role in PD, there are a number 
of unresolved fundamental questions108. Upon neuropathological examination of the oldest 
surviving individuals (90+), 25% show LB pathology without parkinsonism109 and a subgroup 
of PD cases associated with LRRK2-mutation show neuronal loss in SN but lack of LB110. This 
complicates the apparent direct connection between α-syn and neurodegeneration and 
highlights the need for a better molecular understanding.  
Evidence accumulates that misfolded α-syn spread from cell to cell and drive normal α-syn 
into pathological structures in a prion-like way111. In human induced pluripotent stem cells 
(iPSC) exogenous α-syn induce α-syn pathology which is later trafficked between cells112. In 
patients, striatal grafted neurons show LB-like inclusions, indicating a spread from the 
surrounding diseased brain113. In addition, the Braak staging of PD suggests a spatial spread 
where some data support initial aggregation in the gut’s autonomic plexi which extends into 
the CNS114. Since α-syn is central in PD pathogenesis and can be detected in the periphery, 
numerous efforts to measure α-syn as a clinical biomarker has been made. The results have 
been contradictory but most studies report decreased total level of α-syn in CSF and increased 
oligomeric α-syn83,115. The discrepancies is partly due to that α-syn is produced by erythrocytes 
and hence it is difficult to detect only the brain-derived portion in the periphery. To circumvent 
this, methods assessing α-syn derived from neuronal exosomes or aggregated α-syn have 
emerged83,116. In Paper IV of this Thesis a method for detecting nanoamyloids, potentially 
consisting of small α-syn aggregates, is evaluated as a biomarker.  
1.3.2 Dysfunctional protein folding and aggregation 
Protein misfolding and accumulation is a common theme in neurodegenerative disorders, 
including PD. The folding of proteins into their functional three dimensional configuration is 
vital. Cells therefore have an elaborative cellular network to maintain proteostasis, which 
includes protein synthesis, folding and degradation117. To date, 1000-2000 factors are estimated 
to play a role in the system, demonstrating the complexity118. Under physiological conditions, 
proteins are folded to the thermodynamically most favorable configuration, usually with 
hydrophobic amino acids in the core shielded from forming β-sheets and aggregate. However, 
during folding, proteins are only metastable and therefore convert between different 
configurations, making the folding process error prone117. A number of internal or external 
factors, such as genetic mutations, ageing, environmental stressors or overload of the cellular 
machinery, can overturn the protein homeostasis. Most of the folding process and quality 
control take place in the endoplasmatic reticulum (ER). Increased levels of misfolded proteins 
cause so called ER stress which in turn trigger the unfolded protein response (UPR). UPR 
includes halting translation, increasing protein folding factors and increasing ER-associated as 
well as proteosomal degradation, all aiming to lower the protein load. In the case of long-term 




In PD, the neuropathological hallmark is intracellular deposits of misfolded proteins indicative 
of disturbed proteostasis in the cell. If the phenotype is a cause or a consequence is unknown. 
Activation of ER stress and UPR is reported in a number of models as well as in patients. In 
iPSCs derived from PD patients with triplication in SNCA, increased α-syn expression induce 
a phenotype with increased ER stress121. Furthermore, decreasing ER stress alleviates 
dopaminergic cell death in a PD-mouse model122. In patients, several factors involved in UPR 
are up regulated in the SN123,124. The crucial role of ER protein control is also evident in genetic 
forms of PD. Mutations in Parkin, causing autosomal recessive PD, impede how misfolded 
proteins are ubiquitinated and marked for proteosomal degradation63. Thereby, Parkin 
mutations induce ER stress and subsequent neurodegeneration. Several of the substrates of 
Parkin are aggregation prone and found in LB125. As explained above, GPR37 is a substrate of 
Parkin reported to cause ER stress if overexpressed and therefore gained attention in the 
Parkinson’s field44. Even though the ER stress and subsequent UPR response aims to restore 
proteostasis, the chronic stress state is deleterious for the cell as evident in both patients and 
model systems.  
1.3.3 Protein degradation 
Protein aggregation is closely linked to disturbances in the cell’s protein degradation system. 
When misfolded proteins can be refolded by chaperones, targeted with ubiquitin for 
degradation in the proteasome (ubiquitin–proteasome system, UPS) or degraded in the 
autophagy-lysosome pathway (ALP). There is extensive crosstalk between the systems126. If 
degradation fails, protein form amyloids in order to reduce the hydrophobic areas which can 
cause toxic interactions. Both impaired proteosomal and lysosomal degradation is detected in 
brains from PD patients127,128. α-syn has been shown to be degraded by both UPS and ALP129-
131. Both wild-type, mutated and oligomers of α-syn, are reported to cause UPS impairment in 
dopaminergic neurons132-134. Moreover, common toxin models with pesticides and MPP+ show 
reduced proteasome activity both in vitro and in vivo135-137. The involvement of ALP is evident 
by the more than 40 ALP-associated genes linked to PD138,139. These include the most common 
genetic risk factor known today, heterozygotic mutations in GBA1140. GBA1 encodes a 
lysosomal enzyme, glucocerebrosidase, which hydrolyzes glucocerebroside into ceramide and 
glucose when the essential activator saposin C is present. Mutations in GBA1 are preset in 5-
20% of PD patients depending on population138. Mutations causing severe perturbation on 
enzyme activity have increased risk of PD compared to mild mutations, indicating a dose 
effect141. The mechanism by which mutations in GBA1 leads to PD is not fully understood. 
Hypothesis include alterations in lipid composition (see sect. 1.3.4), ER stress caused by 
misfolded of GCase and direct interaction with α-syn decreasing GCase activity resulting in a 
pathogenic positive feedback loop142. In summary, there are multiple evidence that 
perturbations in the cellular protein degradation machinery, leading to a vicious cycle where 
disrupted proteostasis leads to accumulated α-syn which further exacerbates the deficiencies. 
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1.3.4 Lipids in neurodegeneration 
Apart from the theory of protein misfolding and perturbed degradation as key features of PD, 
the role of lipids in the pathogenesis has emerged. The brain has a particularly high expression 
of lipids and most abundant are cholesterol, sphingolipids and glycerosphingolipids143. Lipids 
are essential both for lateral organization of plasma membranes and as regulatory role of 
neuronal physiological function including synaptic activity144. Lipid homeostasis is more prone 
to alteration with increased age which is the greatest risk factor PD145. In neurodegenerative 
disorders specific changes in lipid homeostasis are reported146-149. In PD, the ganglioside GM1 
is reduced specifically in the SN suggested to contribute to dopaminergic vulnerability149. 
GM1, and other sphingolipids, are responsible for the structural stability of lipid rafts. As 
described above, lipid rafts regulate GPCR’s interactions and signaling17. Abnormalities in 
lipid rafts content are reported in early stages of PD possibly affecting raft function146. Much 
remains to be discovered but since protein-lipid interactions are crucial for GPCR physiology, 
these abnormalities are suggested to have judgmental effects.  
Furthermore, the cellular distribution and aggregation of -syn is highly dependent on 
properties of the lipid bilayer103,150. -syn is known to interact with several types of lipids 
including fatty acids, gangliosides and glycosphigolipids151-154. SNCA mutations are clustered 
in the central region of the protein which includes the lipid binding domain as well as the NAC-
domain103,155. Disruption of lipid homeostasis is reported in iPSC after overexpression of -
syn156. In addition, in experimental models, MPTP- treated mice have distinct changes in 
several lipids paralleled with -syn oligomerization105. Specifically, the glycosphingolipid 
GM1 is suggested to inhibit -syn fibrillation in vitro posing a potential mechanism152. Taken 
together, alteration in lipid composition may tip the balance of -syn confirmations and act as 
driving force of oligomerization and fibrillation157.  
Genetic evidence also points towards a role of lipids in neurodegeneration. Sphingolipidoses 
are a group of inherited disorders caused by disturbances in lysosomal lipid metabolism with 
subsequent tissue storage of sphingolipids. Almost all sphingolipidoses, otherwise clinically 
heterogeneous, show neuronal engagement and neurodegeneration158. As explained above, 
GCase, the enzyme translated from the risk gene GBA1, is responsible for degradation of 
glucosylceramide and is hence part of the lipid homeostasis network. PD patients have 
therefore been investigated for substrate accumulation, similarly to the case of 
sphingolipidoses, but this have led to conflicting results159-162. A recent study, however, shows 
reduction of multiple lysosomal hydrolases and concomitant glycosphingolipid substrate 
accumulation163. 
Lipid alterations, either causing general membrane reorganization or specific levels increasing 
-syn’s tendency to form fibrils, now have strong evidence as a mechanistic factor in PD 
development. Furthermore, treatments aiming to normalize lipid levels is under evaluation as 
described in Sect.1.4.2.  
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1.3.5 Mitochondria dysfunction and oxidative stress 
Mitochondrial dysfunction has a distinct role in PD pathogenesis both in experimental models 
and from genetic evidence. Mitochondria are responsible for producing energy in the form of 
adenosine 5’ triphosphate (ATP) in the respiratory chain. In addition, mitochondria regulate 
Ca2+ homeostasis, lipid metabolism and apoptosis164. Mitochondria are the most important 
source of reactive oxygen species (ROS), especially from complex I and III of the respiratory 
chain165. Consequently, mitochondria also have high antioxidant capacity166. If the balance 
between the two is disturbed the cell experience oxidative stress with toxic effects on nucleic 
acids, proteins and lipids. This is judgmental in dopaminergic neurons that have high 
metabolism and are therefore highly dependent on efficient mitochondria164,167.  
The pivotal role of mitochondrial respiration for dopaminergic neuronal survival was evident 
from injections of 1-methyl-4-phenyl-1,2,3,6 tetrahydrodropyridine (MPTP) which caused 
severe parkinsonism in four cases168. Today a MPTP’s derivative, MPP+, is a common 
experimental model in PD research. MPP+ enters the cell through DAT, NET or SERT causing 
a selective cell death169. MPP+ inhibit the mitochondrial complex I and thereby increase ROS, 
leading to cell death170. In idiopathic PD patients, complex I activity is compromised in SN171 
and there is evidence of misassembled complex I, enforcing clinical relevance of complex I 
inhibition172. In addition, several of the genetic causes of PD are directly or indirectly linked to 
mitochondrial function. DJ-1 encodes a chaperone which scavenger mitochondrial ROS and 
PINK detects mitochondrial dysfunction and recruits Parkin to induce autophagy of the 
damaged mitochondria173. Due to both clinical and preclinical evidence, disruption of 
mitochondrial homeostasis is today often used to model neurotoxicity as in Paper III of this 
Thesis.  
1.3.6 Summary of pathogenic mechanisms 
In summary, all the cellular insults described can initiate or support progression of 
dopaminergic cell loss in PD. Therefore, one can argue if clinically diagnosed PD is a collection 
of biological entities, each one needed to be addressed separately96. In addition, there is 
substantial cross talk between the pathways and it is therefore difficult to disentangle in what 
is causative and which cellular responses are reactive, triggered by initial events. The large 
number of molecular signals result in individual combinations responsible for disease. 
Understanding an individual’s combination of biological signals as well recognizing the 
timeline of the molecular proceedings would considerably aid development of disease-




1.4 TREATMENT OF PARKINSON’S DISEASE 
1.4.1 Treatment today 
To date, we can only offer our PD patients symptomatic treatment which aims to elevate the 
reduced dopamine signaling78. The gold standard treatment is the dopamine precursor L-
DOPA, which is converted to dopamine in neurons. In addition, monoamine oxidase B (MAO-
B) or catechol-O-methyltransferase (COMT) inhibitors which reduce the degradation pace of 
dopamine are used174. Early in the disease, or as a supplement at later stages, dopamine agonists 
which activate the D2-class receptors are commonly used. Dopamine agonists are associated 
with lower dyskinesia risk and is efficacious in treating motor fluctuations but is associated 
with an overall higher risk of adverse events than L-DOPA78,174,175. One severe side effect is 
impulse control disorder (ICD), including gambling, compulsive spending and binge eating. 
ICD affects 15-40% of patients treated with oral dopamine agonists and is a common cause of 
discontinuation of medication176,177. Mechanistically ICD is likely linked to a 
hyperdopaminergic state, either due to increased sensitivity of striatal D3 receptors after 
dopamine denervation or over dosing of dopamine to the relatively preserved ventral striatum. 
The latter theory would result in overstimulation of postsynaptic dopamine D2-like receptors 
causing an imbalance in the reward-related cortico-striatal-thalamocortical circuit, stimulating 
impulsivity178. This promiscuity in the ligand-receptor interaction between closely related 
receptors or unbiased activation might be reasons for the disabling side-effects. The side-effects 
have encouraged development of selective D2-agonists and biased D2-ligands which mainly 
activate non-canonical pathways. In preclinical studies biased ligands has been suggested to be 
beneficial in treatment of dyskinesias as well as offering antipsychotic effects without motoric 
inhibition35,179. These advancements point out the possibilities of pharmacological tools and 
also the gaps of knowledge of how the treatments used today affect receptors at the molecular 
level. This is partly addressed in Paper II. 
Figure 3. Summary of pathological mechanisms in PD relevant to this Thesis. Graphic abstract of how -
syn initially misfold, form oligomer species and later fibrils. Oligomeric -syn and fibrils have toxic effects on a 
number of organelles. 
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In addition to dopaminergic treatments aiming to mitigate motor symptoms, symptomatic relief 
for specific NMS such as selective serotonin reuptake inhibitors (SSRI) for depression or 
acetylcholinesterase inhibitors in cognitive decline are used78. This highlights the need to 
modulate several neurotransmitters to successfully treat all aspects of PD. Besides 
pharmacological treatment, some PD patients are suitable deep brain stimulation. Here an 
electrode is surgically implanted in brain nuclei controlling movement which suppress 
symptoms73. None of the available treatments slow down the progressive neuronal death and 
all can cause severe side effects both in short- and long-term78. Therefore, there is a need both 
to understand how today’s treatments affect the remaining dopaminergic neurons as well as to 
disentangle the causative steps in the pathogenesis to identify suitable targets which can halt or 
delay the progression of the disease. 
1.4.2 Potential future treatment 
Since PD, per definition, is progressive the clinical need for disease-modifying treatment is 
evident. As explained, PD is caused by a complex interplay between hereditary and 
environmental factors causing perturbation on multiple cellular pathways to an individual 
extent. This results in a clinical heterogeneity and likely a need for personalized medicine in 
order to slow down disease progression in the individual case180. 
Due to the complex pathogenesis, a long list of potential treatment has been examined. 
Common current treatments such as the MAO-B inhibitor selegiline, the dopamine agonist 
pramipexole181,182 and L-DOPA183, have been suggested to have neuroprotective effects. 
However, all have failed in clinical trials or, the decreased progression rate detected might be 
due to symptomatic relief rather than neuroprotection184-187.  
Large efforts have focused on modulating -syn toxicity due to its pivotal role in PD 
pathogenesis. Targeting -syn’s toxicity through reduced protein synthesis, inhibition of fibril 
formation or increased degradation are all potential treatments184. To date there are clinical 
trials with passive or active immunization for -syn to reduce -syn production. On target 
binding and reduction of free -syn in serum, but not in CSF, has been reported with 
monoclonal antibodies although the effect on disease remains to be investigated188. Different 
methods interrupting -syn aggregation, possibly the key step, have also been evaluated. Since 
phosphorylated -syn has higher tendency to aggregate, treatment with phosphokinase 
inhibitors has been evaluated189. The poor penetrance through the blood-brain-barrier remains 
a challenge as well as risk of off-targets effects. Another line of investigation is to modulate 
lipid levels to reduce -syn’s capacity to aggregate. GM1 binds -syn and inhibit fibrillation 
in vitro152, 190 . In vivo GM1 treatment reduces -syn aggregate size and reverse behavioral 
deficits in rats overexpressing -syn191. In addition, two small clinical studies have reported 
slowing of symptom progression in GM1 treated patients compared to placebo treated 
controls192, 193. Despite the clinical and preclinical findings, the mechanisms through which 
GM1 acts are uncertain, why this is investigated in Paper III. Finally, methods to strengthen 
lysosomal degradation of -syn through its reciprocal relation with GCase activity is in current 
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clinical trials. Recently, a small open labeled non-controlled clinical study of ambroxol, a 
chaperone guiding GCase to the lysosome, showed CNS penetration and increased total -syn 
levels. MDS-UPDRS III, motor symptom subscore, is reported to decrease by 7 points, a 
clinically relevant change. However, this should be interpreted with care due to the study 
design194. Furthermore, a multi-center, placebo controlled phase II trial using a 
glucosylceramide synthase inhibitor is ongoing in PD patients carrying GBA1 mutations 
aiming to reduce potential substrate accumulation. Although extensive research has focused on 
-syn toxicity there are still unmet fundamental questions since -syn aggregation does not 
correlate well with neurodegeneration and neurodegeneration does not require -syn 
aggregation110, 195. Hence, more mechanisms are need to be investigated in order to succeed. 
Orphan GPCRs are often suggested an untapped source of druggable targets due to their 
specific distribution and functional selectivity196. This Thesis focus on one of them, GPR37.  
1.5 SUMMARY 
The heterogeneous PD has been a disease entity for 200 years and a plethora of cellular 
mechanisms have been linked to the disease. The link to α-syn has partly increased our 
understanding but not developed into a better set of diagnostic criteria. Dopamine receptors are 
the primary target in present treatment and despite being extensively studied there is lack of 
understanding how to fine-tune the system. The diversity of GPCRs gives a unique feature to 
induce cell specific responses but we need to understand how the dopaminergic receptors 
interact with other GPCRs and lipids to advance to better pharmacological tools. This will 
require a deeper understanding of molecular interactions as well as increased granularity in our 





The overall aim of this thesis is twofold. Our first aim was to understand how molecular 
interactions modulate the function of GPR37, a Parkinson’s disease associated receptor (Papers 
I, II and III). Here we study GPR37 in live cells using advanced biophysical and 
pharmacological methods. The second aim was to detect structured protein aggregates in blood 
serum of PD patients (Paper IV). Here we take advantage of the extreme sensitivity of one of 
the methods, Fluorescence Correlation Spectroscopy. The specific aims of our studies were to:  
 
I. Elucidate factors contributing to GPR37 membrane trafficking in 
catecholaminergic cells. 
II. Investigate GPR37 interactions with dopamine 2 receptor and functional lipids.  
III. Determine potential cytoprotective effects of GM1 in a GPR37-dependent model. 
IV. Investigate if detection of nanoaggregates in serum can be used as a biomarker in 




3 METHODOLOGICAL CONSIDERATIONS 
Methods used in this Thesis are summarized in the table below and detailed descriptions are 
found in the papers. Below selected methods will be discussed more in depth. 
Method Paper 
Cell culture I, II, III 
Cell transfection II, III 
Generation of stable cell line II 
Fluorescence correlation spectroscopy  I, IV 
Fluorescence cross-correlation spectroscopy I, II 
Confocal laser scanning microscopy I, II, III 
qPCR III 
Dot blot III 
Cell toxicity assays I, III 
HTRF signaling assay III 
Clinical evaluation of PD IV 
3.1 FLUORESCENCE CORRELATION AND CROSS-CORRELATION 
SPECTROSCOPY (FCS/FCCS) 
Fluorescence Correlation Spectroscopy (FCS) is a quantitative analytical method based on 
monitoring with sub-microsecond temporal resolution the spontaneous fluctuations in 
fluorescence intensity that are generated when fluorescent molecules pass through a minute 
observation volume by Brownian diffusion. The technique can detect single molecules and be 
used to measure the concentration of molecules as well as their diffusion in solution and in live 
cells. It can also characterize protein-protein interactions, both in a single-channel mode but in 
particular using a two-channel variant called Fluorescence Cross-Correlation Spectroscopy 
(FCCS). In this Thesis, the methods were used to study GPR37 interactions in Papers I and II, 
and to detect structured amyloid aggregates in the serum from PD patients in Paper IV.  
3.1.1 Principles 
Figure 4A shows an FCS arrangement. The method is extensively described in, e.g., Ref. 197-
201. In brief, a high-numerical aperture microscope objective sharply focuses the incident laser 
light into the sample and light from the sample is collected by the same objective. In order to 
reduce the volume from which light is being detected, a confocal pinhole is placed in an image 
plane of the optics, thereby limiting the collected light in the z-direction. In this way, light is 
collected from a tiny observation volume element (OVE), which in modern instruments is 
about (0.2 – 1)10-15 l. The OVE size depends on the wavelength of light and properties of the 
optical elements. A small size of the OVE is essential to achieve single-molecule sensitivity 
since the background is reduced, resulting in a higher signal-to-noise-ratio. In conventional 
FCS instruments the OVE size cannot be arbitrarily small due to diffraction of light, explaining 
why these instruments are called “diffraction-limited”.  
While the incident laser light is monochromatic, the light collected from the sample is not. It 
consists of elastically scattered incident light, fluorescence from the analyzed fluorophore, and 
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autofluorescence from other molecules present in the sample. Elastically scattered light is 
separated from the emitted fluorescent light by a main dichroic beam splitter. The fluorescence 
is directed through optical filters to spectrally narrow the signal before reaching the detector. 
Avalanche photodiodes are used as detectors since they have single-photon sensitivity. For 
FCCS measurements, a secondary dichroic beam splitter is used to spectrally separate 
fluorescence originating from different fluorophores, and two detectors are used to 
independently detect the signals (see Sect. 3.1.2).   
 
The measured fluorescence intensity depends on the laser intensity, brightness of the 
fluorophore, number of fluorescent molecules in the OVE, detector characteristics, and the 
background from the sample. Due to the spontaneous diffusion of fluorescent molecules, the 
number of fluorescent molecules in the OVE will not be constant. Hence, the recorded 
fluorescent signal will fluctuate around the mean fluorescence intensity (Fig. 4B). The lower 
the average fluorescence intensity, i.e., low concentration of fluorophores, the larger is the 
relative intensity variation due to each fluorescent photon. Figure 5 depicts time-series of 
fluorescent fluctuations in high-concentration (A) and low-concentration systems (B) 
visualizing the difference in impact of one photon on fluctuation variability. Thus, unlike other 
analytical techniques, FCS is especially suitable for low-concentration systems such as 
Figure 4. Schematic FCS arrangement, fluctuation detection, and temporal autocorrelation analysis. A) 
A confocal microscope arrangement illuminating fluorescent molecules diffusing in the sample. Emitted 
photons are guided through filters and a pinhole to reduce background before reaching the APD detector. B) 
Fluorescent intensity fluctuations are recorded over time. C) Fluctuations are analyzed for self-similarity by 
temporal autocorrelation analysis to give an autocorrelation curve G(τ). From the autocorrelation curve the 
number of molecules N and characteristic decay time (τD) can be deducted. 
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fluorescently tagged proteins which move randomly in live cells. The time-course of the 
fluctuation depends on the diffusion rate of the molecule and the size of the OVE. Thus, the 
OVE size needs to be determined using standard solutions of fluorescent molecules with known 
diffusion properties. In this work, Rhodamine 6G was used as a standard for instrument 
calibration and OVE size determination. 
In order to extract relevant information from the fluorescence intensity fluctuation time series, 
several different methods are being used. The most commonly adopted is to analyze the 
variations over time using so-called temporal autocorrelation analysis. Here the time-dependent 
fluorescence fluctuation F(t) is defined as the difference between the fluorescent signal F(t) 
at time point t, and the average fluorescent signal over the whole time series F(t) 
𝛿𝐹(𝑡) = 𝐹(𝑡) − 〈𝐹(𝑡)〉,     (1) 
where the chevron brackets denote average values over time.  
The normalized (temporal) autocorrelation function G() is the correlation of a time series with 
itself shifted by a lag time , as a function of the lag time . The lag time  is varied to identify 
whether there is a characteristic value after which the correlation is being lost. The normalized 
autocorrelation function is calculated as 
𝐺(𝜏) = 1 +
〈𝛿𝐹(𝑡)∙𝛿𝐹(𝑡+𝜏)〉
〈𝐹(𝑡)〉2
.     (2) 
Figure 4C shows an example of G(), also called the autocorrelation curve. The average 
number of molecules in the OVE can be determined from the amplitude of G() at lag time 
zero, and the diffusion time from the characteristic decay time (τD). In order to derive these 
values, the autocorrelation function is fitted to theoretically derived model functions for 2D or 
3D diffusion, depending on the system investigated. For example, when analyzing receptor 
diffusion and interactions in the plasma membrane of live cells in Paper I, a 2D model was 
used. In Paper IV, where measurements were made in blood serum, a 3D model was used.  
3.1.2 Fluorescence cross-correlation spectroscopy (FCCS) 
FCS may also be applicable for investigations of interaction between two molecules, e.g., a 
small ligand binding to a membrane. However, the diffusion coefficient in solution depends on 
molecular weight, MW, as MW-1/3. Hence, interaction between two molecules of similar 
Figure 5. The effect of concentration on 
fluorescence intensity fluctuation. A) At high 
concentrations, the mean intensity is high and the 
relative amplitude of the fluctuations is small. B) 
At low concentrations, the mean intensity is low, 
and the relative amplitude of the fluorescence 
intensity fluctuations is comparatively high. 
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molecular weight does not give an easily detectable change in diffusion time202, 203 . To enable 
studies of interactions between molecules of similar size, fluorescence cross-correlation 
spectroscopy (FCCS) was developed. The principles are shown in Fig. 6 and the theory is 
reviewed in Ref. 200. In FCCS, fluorescence intensity fluctuations are recorded for two 
spectrally distinct fluorophores simultaneously, hereafter called green and red, using a two-
channel instrument. The OVEs generated by two lasers overlap, enabling simultaneous 
excitation of both fluorophores, but the detection pathways are separated (Fig. 6A). For each 
fluorophore, temporal autocorrelation analysis is used to derive the autocorrelation function 
but the intensity fluctuations of each fluorophore is also compared to each other. If the two 
fluorophores move together through the observation volume, the intensity variations in the two 
channels will co-variate as a sign of complex formation (Fig. 6B). This generates two 
autocorrelation curves and one cross-correlation curve (Fig. 6C). Assuming optimal conditions, 
the normalized cross-correlation function is described as  
𝐺𝐶𝐶(𝜏) = 1 +
〈𝛿𝐹𝑔𝑟𝑒𝑒𝑛(𝑡)𝛿𝐹𝑟𝑒𝑑(𝑡+𝜏)〉
〈𝐹𝑔𝑟𝑒𝑒𝑛(𝑡)〉〈𝐹𝑟𝑒𝑑(𝑡)〉
.    (3) 
The amplitude of the cross-correlation curve is proportional to the degree of dually labeled 
molecules200. In order to normalize between cells, the cross-correlation amplitude is divided by 
either of the autocorrelation amplitudes at lag time zero, to have a measure of the degree of 
binding. This generates a dimensionless “relative cross-correlation amplitude” (RCCA), in 




,     (4) 
where GAC(τ) is the autocorrelation of green fluorophore.  
 
Figure 6. Schematic FCCS arrangement. A) FCCS arrangement where two lasers illuminate two spectrally 
separated fluorophores. Emitted light is separated to two detectors. B) Intensity fluctuations are recorded from 
the two detectors separately. C) The corresponding temporal autocorrelation curves G(τ) (green and red) and 




In Papers I and II, fluorescence intensity fluctuations where recorded at the apical plasma 
membrane of live N2a cells in order to evaluate GPR37 movement in the plasma membrane as 
well as molecular interactions. In Paper I, FCS measurements analyzed with temporal 
autocorrelation analysis was applied to evaluate diffusion of GPR37 and FCCS was applied to 
elucidate GPR37 interaction with GM1-enriched lipid rafts as well as the proposed ligand 
PSAP. In Paper II, FCCS was applied to study interaction between GPR37/GPR37L1 and D2R.  
In Paper IV, FCS was applied to detect Thioflavin T (ThT)-positive -sheet enriched structures, 
hereafter called nanoamyloids/nanoplaques, in the blood serum of PD patients. The FCS 
detected fluctuations were analyzed by an automated program detecting fluorescent “peaks”, 
indicating the passage of a ThT-positive amyloid structure through the observation volume. 
The number of peaks was then normalized to the measurement time to determine the frequency 
of single events occurrence (fSEO) in the OVE. The fSEO is given in units per hour (h
-1). The 
average size of the nanoamyloids was determined by temporal autocorrelation analysis as 
explained above. The individual autocorrelation curves were normalized to the same amplitude 
at τ = 10 µs, and the autocorrelation curves from the patient and the control groups, were 
combined to an average autocorrelation curve for each group. To identify whether 
nanoamyloids of different size are present in the serum, without having to specify the number 
of components in advance, the average autocorrelation curves were fitted using the Maximum 
Entropy Method (MEMFCS) that is specifically developed for bias-free fitting of FCS 
measurements in highly heterogeneous biological systems204. The validation experiments of 
the assay can be found in Ref. 205.  
3.1.4 Methodological considerations 
The number of methods studying molecular interactions are now numerous. FCCS has proven 
to be well suited for live cell experiments since the method is almost non-invasive, 
measurements do not perturb the system’s dynamics, and the method has a single-molecule 
detection sensitivity. Other common methods to study molecular interactions, such as 
Förster/fluorescence resonance energy transfer (FRET) or Proximity Ligation Assay (PLA), 
differ fundamentally from FCCS in that they measure spatial proximity. In order for non-
radiative energy transfer to occur in FRET or ligation in PLA, the two molecules have to be in 
close proximity, maximum 10 nm apart. The close proximity, however, does not necessarily 
prove that the proteins interact. FCCS, on the other hand, can detect simultaneous movement 
which indicates functional complex formation. 
As all methods, FCS/FCCS have their limitations. Ref. 199, 200, 203 provide details. In brief, 
fluorescence variations within the observation volume can be caused by other processes than 
molecular diffusion. This includes photophysical and photochemical processes such as 
blinking and bleaching which can change the amplitude, shape and characteristic decay time 
of the autocorrelation curve. In cell measurements, an autofluorescent background may 
decrease the signal-to-noise-ratio. In FCCS, the situation is further complicated by bleed-
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through between channels which can give false positive cross-correlations. Due to the single-
molecule-detection limit, FCCS is very sensitive to photon noise and fluorophores with high 
photostability and quantum yield are needed. This limits the number of available fluorophores 
since most of the fluorophores in the far red part of the spectrum, desirable to limit cross-talk, 
do not fulfill the brightness requirement. There are several strategies to asses bleed-through. In 
Paper I and II, most essential FCCS results were validated using sequential illumination, which 
separates the spectrally distinct fluorescence signals temporally, in order to confirm a true 
cross-correlation. In addition, one should examine cross-correlation at the time lag of the triplet 
state which indicate that one fluorophore is detected in both channels. To perform cross-talk 
free FCCS measurements is not always possible. Under such conditions, one can compare the 
RCCA to the RCCA value measured in a negative control experiment where the same 
fluorophores are used, as in Paper II. Finally, bleed-through vary with brightness, which is not 
uniform in live cells due to local environmental differences and/or due to oligomerization-
inducing treatments. These differences are more difficult to account for. Therefore, findings by 
FCCS should be interpreted carefully and, whenever possible, be validated with other methods.  
3.2 CELL TOXICITY ASSAYS 
Determining cell viability is crucial in several cell culture studies and there is a plethora of 
different methods. The methods assess various cellular functions such as cell membrane 
permeability, metabolic activity, ATP production, or DNA synthesis206. The most appropriate 
method depends on cell type, culture conditions and which hypothesis to be tested207.  
Metabolic activity is usually assessed via detection of oxidation-reduction reactions. MTT 
assay is one of the most widely used cell viability assays in which soluble yellow MTT ((3-
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) is converted into insoluble 
purple formazan crystals. The exact cellular mechanism is not completely understood but likely 
involves transfer of electrons to MTT from reducing molecules. Under most culture conditions, 
the amount converted is proportional to the number of viable cells. The crystals are solubilized 
and the absorbance is analyzed. The analysis is robust and widely acknowledged207. Rezasurin 
is an alternative to MTT. Rezasurin is a dark blue non-fluorescent compound which upon 
entering the cells is reduced irreversibly to resorufin, a pink and fluorescent compound. Since 
rezasurin is fluorescent, the assay is considered slightly more sensitive than MTT. It is also less 
toxic to cells and requires less laboratory steps. However, under certain conditions interference 
of fluorescence can lead to false results at higher cell density and resorufin can be further 
reduced to non-fluorescent hydroresorufin, giving false read out207. In Paper I, MTT is used, 
whereas in Paper III rezasurin was chosen due to increased specificity as well as the reduced 
number of steps, reducing technical variation. Both these assays, however, measure cellular 
metabolism by oxidation-reduction reactions in the mitochondria and are appropriate when 
assessing adherent cells with several treatment groups where the throughput is essential. 
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3.3 CELL SIGNALING ASSAYS 
Cell transduction from GPCR is one of the most extensively studied topics in biology. Since 
the network consist of numerous molecules and are highly entwined, there are countless of 
assays designed to study cell transduction at different stages of the cascade. Depending on the 
question asked, different targets should be investigated. Signals far downstream of the ligand-
receptor interaction event can be generated by more than one signaling pathway7. Detecting 
those are therefore more difficult to directly link to the GPCR activation but potentially indicate 
the functional outcome.  
Changes in cAMP levels are relatively upstream in the signaling cascade and hence, commonly 
measured directly or indirectly as a marker of GPCR activation. Homogeneous time-resolved 
fluorescence (HTRF) assays combines FRET technology with time-resolved measurement in 
order to reduce background noise. It has been applied to examine kinase activity, protein-
protein interactions and GPCR signaling via determination of cAMP levels208. In principle, we 
used is a competitive immunoassay using d2-labeled cAMP and Eu3+ cryptate-labeled anti-
cAMP antibody. The close proximity of the Eu3+ cryptate donor and the d2-acceptor upon 
binding of the antibody to labeled cAMP will allow FRET from the long-lived fluorescent 
donor to short-lived fluorescent acceptor. Unlabeled cAMP in cells compete for d2-antibody 
binding and FRET signal decreases (Fig. 7). Eu3+ cryptate has a large Stokes shift and long 
fluorescent lifetime which introduces a time delay, 50-150 µs, between excitation and 
fluorescence emission. Together those properties reduce non-specific fluorescent signal and 
hence increase sensitivity. In addition, in each well HTRF emissions are measured at two 
different wavelengths, 620nm (donor) and 665nm (acceptor) which allows the emission at 620 
nm to be used as an internal reference to reduce well-to-well variations.  
 
Figure 7. Schematic drawing of operation of HTRF. A) When Eu3+ cryptate-labeled anti-cAMP binds d2-
labeled cAMP the FRET pair is in close proximity and energy transfer occur. B) Cellular cAMP will compete 
for binding anti-cAMP and the FRET signal will decrease with higher concentration of endogenous cAMP.  
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In Paper III this assay was used to detect change in cAMP levels in HEK cells at baseline and 
with GM1 treatment. Since the G protein-coupling of GPR37 and downstream signaling targets 
are still partly undetermined, an assay to quantify second messenger was chosen. HTRF assays 
are highly sensitive, optimized for homogenous assays and well established in high throughput 
assays. In addition, they have previously been used to characterize orphan receptors209, 210.  
3.4 CLINICAL EVALUATION OF PARKINSON’S DISEASE 
Since PD is a highly heterogeneous disease, the clinical evaluation of disease burden needs to 
include several aspects. In addition, since the pathophysiological understanding is insufficient, 
detailed clinical evaluation can reveal if certain symptoms are linked to prognosis, treatment 
response or specific biomarkers. The scales used to correlate nanoplaques with clinical aspects 
in Paper IV are discussed below. All the patients included in the study were included at the 
Academic Center of Neurology in Stockholm. The study was approved by the Regional Ethics 
Committee in Stockholm. 
3.4.1 Parkinson symptoms  
To assess the full clinical spectrum of PD symptoms the most widely used scales are Unified 
Parkinson’s disease rating scale (UPDRS), and the more elaborative Movement Disorder 
Society-UPDRS (MDS-UPDRS). Both scales consist of four parts, non-motor and motor 
experiences in daily life (part I and II respectively), motor examination (part III) and motor 
complications (part IV)211. Prior to the development of UPDRS, various scales were used in 
different centers making inter-center comparisons difficult. Today, the scales are the gold 
standard in clinical practice, as well as clinical research. Both has been evaluated with low 
inter-rater variability. As UPDRS is shorter than MDS-UPDRS, it is plausible to use in daily 
clinical work. However, it has also been criticized to lack questions regarding important non-
motor symptoms (NMS)211. This highlight the continuous consideration between optimal and 
feasible clinical characterization in daily clinical work. To circumvent this there are formulas 
to convert UPDRS score to MDS-UPDRS, either for day-to-day evaluation and for research 
properties212, 213. Both these studies report significant concordance for part II and III, while part 
I and IV are structured differently and hence not appropriate to convert.  
The clinical evaluation of patients in Paper IV was assessed at the end of their doctor’s 
consultation. A vast majority of the patients are evaluated by the same rater which decrease 
variability between observations. However, due to the discomfort, patients were not instructed 
to avoid dopaminergic medication prior to the visit, which affects the motor score ratings. Only 
the motor examination (UPDRS III) was converted using Goetz et al formula for research 
purposes as these show excellent correlation between UPDRS and MDS-UPDRS213.  
3.4.2 Disease severity 
The Hoehn and Yahr (H&Y) scale is the reference standard to assess PD severity and 
progression214. First published in 1967, it classifies PD patients from stage 1-5, from unilateral 
mild disease (stage 1) to bilateral disease without postural stability (stage 2), to disease 
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affecting balance (stage 3) and further to severe disability (stage 4) and confinement in bed or 
wheelchair (stage 5)215. Since each stage is broad, the scale was modified to include 0.5 
increments to increase granularity. It was designed give an overview of functional disability 
and objective impairment. It is fast to complete and easy to use, also for non-movement 
disorder specialists. The stages are highly clinically relevant but the combination of disability 
and impairment leads to ambiguity and due to the broad stages the scale is less sensitive to 
detect clinical change. In addition, even though the modified scale is more commonly used 
today than the original, there is a lack of clinimetric studies214. Even with those flaws, H&Y is 
still a standard scale which is highly useful in PD research, partly due to that it is well 
recognized among colleagues.  
3.4.3 Non-motor symptoms scales 
As described above, the gold standard for evaluation of motor symptoms in PD is UPDRS III. 
For specific NMS there are numerous scales used with various levels of validation. In 2006 the 
NMS screening questionnaire (NMSQuest) was developed due to the lack of scales assessing 
the wide range of NMS in PD in a simple 30-item, yes/no, self-reporting form216. NMSQuest 
is today widely used and validated at all stages of PD and it correlates with disease burden216,217. 
Since our understanding of NMS is increasing the preliminary MDS-NMS, a comprehensive 
clinician reported outcome scale, was launched in 2015. The pilot version was evaluated and 
after additional modifications a finalized version was published 2019 and is under current 
validation218. The scale is estimated to take 15-40 min to complete which is significantly longer 
than the 5-7 min for NMSQuest. In a healthcare system highly pressed with time, NMSQuest 
has a strong an advantage in order to achieve complete data sets in general PD patients, not 
only patients included at academic centers or included in clinical research.  
3.4.4 Cognitive decline  
After 20 years, up to 80% of patients experience cognitive decline related to PD219. Two 
subtypes of cognitive dysfunction have been suggested, executive dysfunction and 
visuospatial/semantic fluency dysfunction. Detailed neuropsychological testing covers all 
domains although it is time consuming and not readily available why screening scales are 
developed. MDS recommends three scales; Parkinson's Disease‐Cognitive Rating Scale (PD-
CRS), Mattis Dementia Rating Scale Second Edition (DRS-2) and Montreal Cognitive 
Assessment (MoCa)220, where the latter is used in this Thesis. The strengths of MoCa is that it, 
in comparably short administration time, assess global cognitive function including executive 
dysfunction. For general dementia screening in Sweden, Mini Mental State Examination 
(MMSE) is commonly used. In MMSE, the coverage of executive abilities, visuospatial and 
constructional praxis is limited. Therefore, the scale is less appropriate for PD dementia 




3.4.5 Depression  
In cross sectional studies 30-40% of PD patients have depressive like symptoms222. The gold 
standard for depression is the diagnosis criteria in Diagnostic and Statistical Manual of mental 
disorders (DSM). Since many symptoms of PD overlap with symptoms of depression there are 
diagnostic difficulties. In addition, patients with cognitive decline are difficult to evaluate 
properly regarding emotional symptoms and, on the contrary, depression can be perceived as 
cognitive decline due to psychomotor changes. In general, observer-rated scales are preferred 
and are therefore in focus in recommendations. Hamilton Depression Rating Scale (Ham‐D), 
Montgomery‐Asberg Depression Rating Scale (MADRS) and Beck Depression Inventory 
(BDI) are generally recommended223. MADRS is originally designed to evaluate depression 
depth and not for diagnostic screening purposes. However, there are reports suggesting cut offs 
and it is today recommended for screening as used in this Thesis224. Compared to other scales 
MADRS has relatively few somatic items which is suitable for PD patients. It is specifically 





4 RESULTS AND DISCUSSION 
Molecular interactions can predict a protein’s function and indicate physiologically relevant 
networks. However, interactions can also be a sign of pathological incidents in a cell, as in the 
case of protein aggregation. The work summarized in this Thesis focuses on two aspects that 
are important for Parkinson’s disease (PD) pathogenesis. First, molecular interactions of 
disease-related GPCRs with subsequent signaling alterations and secondly, the formation of -
synuclein (-syn) amyloid aggregates which is the pathological hallmark of PD. Regarding 
GPCRs, we have specifically studied GPR37, its protein-protein interactions important for 
subcellular localization as well as effects of protein-lipid interactions. Regarding amyloid 
formation, we have detected -enriched protein aggregates, nanoplaques, in blood serum from 
PD patients and correlated them with clinical parameters. These different interactions are 
studied by a range of methods of which fluorescence correlation spectroscopy (FCS) play a key 
role. In the following section a summary of the results in Paper I-IV are discussed in a thematic 
approach. For a comprehensive description, the reader is referred to the full papers.  
4.1 INTERACTIONS AFFECTING TRAFFICKING OF GPR37 (PAPER I AND II) 
In heterologous systems GPR37 is primarily expressed intracellularly33, 44. According to the 
literature, this is due to disrupted trafficking which enhances the risk of toxic protein 
accumulation potentially leading to neurodegeneration. Finding methods to traffic GPR37 to 
the plasma membrane is therefore potentially of pharmacological relevance. Different methods 
to increase GPR37’s association with the plasma membrane are therefore applied and further 
evaluated in this Thesis. In general, membrane expression depends on a number of intra- and 
extracellular variables including ligand concentration, chaperone availability, and β-arrestin 
recruitment. In particular, GPR37 membrane localization is enhanced by inducing molecular 
chaperones, cell differentiation, and co-expression of GPCRs, including D2R33, 67, 225 . The 
GPR37-D2R interaction further studied in Paper II.  
In Paper I, prosaposin (PSAP) was evaluated as a factor determining GPR37 subcellular 
localization in N2a cells. At the time when we commenced our studies, PSAP was recently 
published to be the endogenous ligand for GPR37 and GPR37L1 and, as such, a potential 
regulator of membrane trafficking49. Since PSAP is expressed by most mammalian cells and is 
secreted extracellularly, conditioned media from N2a cells was tested for the presence of PSAP 
using Western blot. The concentration of PSAP in the media was several times higher than the 
suggested EC50 of 7 nM for PSAP at the receptor
49. A substantial fraction of GPR37 was 
therefore suggested to be bound to PSAP in the model system used. In order to block 
extracellular PSAP from binding to the cell surface, an antibody targeting the neurotrophic 
region of PSAP was added to the cell media. After the antibody addition a pronounced decrease 
in surface density of GPR37 was noted and Western blot showed a sharp decrease of free PSAP 
in the media (Fig. 8). In addition, a positive cross-correlation between GPR37-tGFP and the 
PSAP-derived peptide TX14(A) was identified indicating a complex formation between 





The traditional view of ligand-regulated membrane association is that agonists induce 
internalization. Reduced agonist availability, as in the case of immunoabsorption, would 
therefore increase membrane density. GPCR trafficking is probably more complex. There are 
reports of increased surface density of receptors by agonist treatment, e.g., for the delta opioid 
receptor226. There is also an increasing group of GPCRs with primarily intracellular function 
of which activation and trafficking is less well characterized. Furthermore, PSAP can have a 
modulatory role of GPR37 trafficking without having all the properties of an agonist. All of 
these alternatives are possible explanations of the observed phenomena. 
In Paper II, the interaction between GPR37 and D2R was further studied. In in vitro studies, 
the two receptors interact33, 34. Co-expression of the receptors was also reported to increase 
GPR37 trafficking to the plasma membrane indicating an interaction important for its function. 
However, the interaction had not been studied in live cells. Stable N2a-GPR37-eGFP cells, 
transiently transfected with D2R-TdTomato of either the postsynaptic or the presynaptic splice 
form (D2RL-TdTomato and D2RS-TdTomato, respectively), were studied using FCCS to 
determine if GPR37-eGFP and D2R-TdTomato diffuse as a complex in the plasma membrane 
(Fig. 9). At baseline, we detected a cross-correlation between N2a-GPR37-eGFP and D2RL-
TdTomato, indicating complex formation. The relative cross-correlation amplitude (RCCA) 
was low, indicating that only a small fraction the receptors formed heterodimers. RCCA 
between GPR37-eGFP and D2RS-TdTomato was at the same range as a previously published 
negative control. Possibly, the difference between the D2R splice forms can be explained by 
that D2RL, under these experimental conditions, has a slightly better trafficking capacity of 
GPR37 than D2RS.  
Figure 8: Immunoabsorption of extracellular PSAP in cell media. Quantification and representative 
images of GPR37 density at the plasma membrane expression before and after anti-PSAP treatment and the 




However, from imaging it was evident that a large fraction of GPR37 was located 
intracellularly, despite D2R co-expression. To evaluate if increased trafficking of GPR37 to 
the plasma membrane could increase the fraction of GPR37-D2R heterodimer receptor 
complexes, we used 4-phenylbutyrate (4-PBA). 4-PBA is a chemical chaperone which 
facilitates correct protein folding and has previously been used to augment GPR37 expression 
at the plasma membrane225. Treatment with 4-PBA increased the fraction of interacting GPR37 
with both splice variants of D2R (Fig. 10).  
 
Figure 9. FCCS measurements in live cells. A) Fluorescent intensity fluctuations recorded at the apical 
membrane of N2a cells expressing GPR37-eGFP and D2RL-TdTomato. B) Corresponding temporal 
autocorrelation curves (red and green) and cross-correlation curve (black) between GPR37 and D2RL. C) 
Temporal autocorrelation curves (red and green) and cross-correlation curve (black) between GPR37L1 and 
D2RS.  
 
Figure 10. Complex 
formation of GPR37 and 
D2R in live cells A) 
Representative images of N2a 
cells expressing GPR37 and 
the two isoforms of D2R. 
GPR37 and D2RL interact 
under baseline conditions. B) 
Induction of GPR37 
trafficking to the plasma 
membrane by 4-PBA 
treatment increased the 
fraction of GPR37 interacting 




Heterodimerization can also be affected by pharmacological tools. In order to investigate if this 
was the case for the GPR37-D2R complex we studied the fraction of interacting molecules 
during pramipexole treatment, a clinically commonly used D3/D2 dopamine agonist. 




GPR37L1 is often examined in parallel with GPR37 to compare their functions and the 
receptors are often reported to have similar effects49, 52, 70. In our live cell studies, the RCCA at 
baseline was higher for transiently transfected GPR37L1-D2RS than for GPR37L1-D2RL, 
opposite of the result of GPR37, and indicating heterodimerization. In contrast to GPR37, 
GPR37L1 is in most cellular models primarily located in the plasma membrane, without any 
need of interaction partners or chemical chaperones. This was also evident in our model and 4-
PBA treatment did not increase the RCCA levels detected for GPR37L1-D2R. Furthermore, 
GPR37L1-D2R binding was not changed with pramipexole treatment, indicating a specific 
impact on the GPR37-D2R heterodimerization. This finding also excludes most possibilities of 
that 4-PBA or pramipexole treatment changed experimental factors which could influence the 
fluorescent properties leading to misinterpretations. However, for all the experimental settings 
examined GPR37L1-D2R the RCCA is low and could not be increased with pharmacological 
treatments, risking misinterpretation due to artifacts such as bleed-through. Hence, the results 
for GPR37L1 should be interpreted with care. 
Paper II was the first to suggest GPR37-D2R heterodimerization in live cells. In addition, a 
clinically relevant dopamine agonist was shown to increase the fraction of interacting 
molecules, which can be of importance for clinical practice. D2R interacts with a large number 
of other GPCRs and dimerization alters its function. D2R dimerization with A2AR, a receptor 
also interacting with GPR37, shifts the preferred D2R coupling from Gi to β-arrestin 
signaling30. How the complex formation between GPR37 and D2R affects downstream 
signaling and physiological outcome remains to be investigated. From a clinical perspective 
Figure 11. Dopamine agonist 
treatment increases fraction of 
GPR37-D2R complexes. A) 
Pramipexole treatment increases 
heterodimerization between GPR37 
and both splice forms of D2R. B) 
After 4-PBA treatment, dopamine 
agonist treatment further enhanced 
complex formation between GPR37 
and both splice forms of D2R.  
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the molecular pathways need to be further investigated, especially since the interaction is 
augmented by pramipexole treatment. Potentially, the shift in equilibrium towards 
heterodimerization and its role on trafficking is a drug target by itself. 
The results obtained in this cellular model require further studies in biologically more relevant 
systems due to the study’s limitations. First, increased protein levels at the plasma membrane, 
as in a plasmid-transfected cell line, can induce interactions not naturally occurring. In order to 
reduce the risk, a stable cell line was used for GPR37 since those generally express lower 
protein levels. In addition, the structurally similar GPR37 and GPR37L1 were analyzed in 
comparable manners resulting in different outcomes which indicates a biological reason for the 
differences. Secondly, bleed-through can cause false positive cross-correlations which needs 
to be accounted for. The GPR37-D2R interaction and the increased cross-correlation amplitude 
after pramipexole treatment have been detected using sequential illumination which lower the 
risk of bleed-through being a major component of the cross-correlation detected. Relative 
changes can be interpreted but the lowest RCCA values in this study need further validation to 
exclude are methodological artifacts with high certainly. The data in Paper II support previous 
in vitro data and add one more part of the puzzle of GPR37’s interactome.  
4.2 GPR37 INTERACTION WITH GM1 (PAPER I AND III) 
Lateral organization of the plasma membrane into ganglioside GM1-enriched lipid rafts are 
central in coordinating GPCR function17. In addition, GM1 has gained researchers’ attention 
for decades due to its neuroprotective and neurotropic effects seen in vitro and in vivo. A 
number of pathways including potentiation of neurotrophins’ effects227 are suggested. As 
explained, expression levels of GM1 decrease specifically in PD149 and GM1 inhibits -syn 
from forming -sheets152. Therefore GM1 is suggested to be key to avoid neurodegeneration228. 
As such, the interaction between GM1 on GPR37 were investigated in Paper I and III.  
In Paper I we sought to investigate if lipid rafts sorted GPR37 at the plasma membrane. To 
study lipid rafts, Cholera toxin β-subunit (CtxB), which binds GM1, is often used as a marker 
for the nanodomains in cellular studies. In differentiated N2a cells, GPR37-tGFP was shown 
to colocalize with CtxB-Alexa594 in the presence of PSAP (Fig. 12). Using FCCS a positive 
cross-correlation between the GM1-marker and GPR37-tGFP was detected indicating that 
GPR37 forms a complex with GM1. Indeed, treatment with cholesterol depleting agents which 
Figure 12. GPR37 colocalize with GM1 
A) Representative images of GPR37 
colocalizing with the GM1 marker CTxB 
in the presence of PSAP indicating a 
sorting of GPR37 into lipid rafts in N2a 
cells. B) PSAP-immunoabsorption 
reduced co-localization between GPR37 
and GM1.  
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disrupts the lipid rafts resulted in a loss of cross-correlation between GPR37-GM1 and GPR37-
TX14(A). This indicates that the three molecules have a functional connectivity, either by 
direct physical interaction or as members of a larger signaling domain.  
Due to the interaction between GPR37 and GM1 studied in Paper I, we aimed to identify the 
functional outcome of the interaction in Paper III. In a toxin model using MPP+, we report a 
GPR37-specific rescue with exogenous GM1 in non-differentiated N2a cells compared to N2a-
eGFP (Fig. 13). This effect was detected in both stably overexpressing cells as well as 
transiently transfected. In transient transfections, we included D2RL since overexpression of a 
receptor could alter the lateral organization of the plasma membrane inducing the differences. 
However, this was not the case and D2R-N2a cells were not rescued by GM1 treatment, 
indicating a specific effect of GPR37. The two models have different characteristics. 
Transiently transfected cells are in general under high cellular stress due to the recent 
transfecting event and express high levels of protein, potentially overwhelming the protein 
quality system. Stable cell lines express lower protein levels which allows for long-term 
survival. Results from stable cell lines are usually more reproducible as the variability and 
toxicity induced by the transfection event is diminished. On the other hand, generation and 
propagation of stable cell lines can induce differences due to long-term adaptation or 
cytogenetic instability which has been reported for a number of cell lines229, 230. Hence, the two 
models are complimentary and help to exclude model-induced errors.  
 
Studying signaling events are crucial in understanding GPCR function. Without a confirmed 
ligand, studies are more complex and the literature for the preferred G protein-coupling of 
GPR37 is partly contradictory. During baseline conditions, HEK-GPR37-eGFP cells show 
decreased cAMP levels compared to HEK-eGFP, interpreted as increased Gαi- activity. Since 
the endogenous ligand of GPR37 is undetermined we cannot differentiate if the receptor is 
constituently active or if the media contain the endogenous ligand. After 2 hours of GM1 
treatment the reduced cAMP levels are normalized, in indicating an altered effect on GPR37-
signaling (Fig. 14). GM1 treatment did not affect cAMP levels in D2R transfected cells but  
Figure 13. GM1 treatment is cytoprotective in a GPR37-dependent model. A) Stable GPR37-eGFP-N2a 
cells are specifically rescued with GM1 treatment towards MPP+ treatment. B) Transiently transfected N2a 





D2R does not exhibit constituent activity and the absence of change is therefore more difficult 
to interpret. The reduced Gαi-signaling, initially counterintuitive of the positive effect of 
GPR37 on cell viability, can be explained by a shift in G protein-coupling upon GM1 treatment 
responsible for the effect. The fact that we detect a direct effect of GPR37 signaling strengthen 
the conclusion that cytoprotective effects of GM1 treatment is partly dependent on the function 
of GPR37. 
The reduced Gαi-signaling intensity can be due to both rearrangement in the micro-
environment by addition of exogenous GM1 as well as direct protein-lipid interaction. GM1 is 
reported to directly interact with the GPCR serotonin 1A receptor (5-HT1A) via a sphingolipid 
binding domain (SBD)231. The SBD consist of a conserved combination of aromatic, basic and 
turn-inducing amino acid residue. Interestingly, we identify a motif in an extracellular loop of 
GPR37 which has high similarity to the known SBD in 5-HT1A. Modeling suggested similar 
loop configuration. The effects reported could hence be due to a direct protein-lipid interaction 
and the positive cross-correlation detected in Paper I would not only be due to GPR37 
localization in lipid rafts. 
Apart from the direct effect on GPR37 signaling, other possible mechanisms of GM1 effects 
was investigated in Paper III. GM1 is reported to interact with chromatin to regulate gene 
expression232. GPR37 can, under certain conditions, confer a cytoprotective effect why 
increased expression of GPR37 could explain the toxin-resistant effect detected. However, 
GPR37-expression was not changed; neither in endogenously expressed GPR37 in N2a-eGFP 
or in the stably overexpressing N2a-GPR37-eGFP measured by qPCR. Furthermore, our stable 
N2a-GPR37-eGFP cell model was found to express lower levels of endogenous GM1. This 
phenomena, induced by knocking down the GM1-producing enzyme B3GALT4, has been 
reported to cause increased vulnerability to MPP+233. In our model, there is no increased 
susceptibility to MPP+ paralleled to the GM1 decrease and no change in B3GALT4 levels 
evaluated by qPCR. This indicates that two different mechanisms are studied or that GPR37 
expression rescues the more susceptible phenotype.  
As the proposed functions of GM1 are plentiful, it is difficult to separate the distinct functions. 
To mutate the key amino acids of the SBD into amino acids with contrasting properties is one 
alternative to disentangle lipid-raft formation from ligand-like interaction. However, this 
assumes that GPR37 folds, inserts into the plasma membrane, and binds other potential ligands 
Figure 14. GM1 alters GPR37 signaling. 
Under baseline conditions HEK-GPR37 contain 
lower levels of cAMP, indicative of a Gi-
coupled receptor which is either constituently 
active or presence of endogenous ligand in the 
media. After two hours of GM1 treatment the 
cAMP levels are normalized. 
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in the media correctly, despite having another primary structure. Furthermore, even indications 
of a direct interaction can be interpreted differently. GM1 interaction can either directly inhibit 
GPR37 signaling, analogous to an inverse agonist, or block binding of an endogenous ligand 
in the media. The lack of pharmacological tools is a major issue when studying orphan 
receptors and hinders progress.  
4.3 DETECTION OF NANOAMYLOIDS IN PD PATIENTS (PAPER IV) 
Paper IV focuses on detecting improper protein-protein interactions as a sign of disease. Brain 
protein aggregates is the characteristic of neurodegenerative diseases. In PD, amyloid fibrils of 
α-synuclein (α-syn) is the main constituent and has therefore been appreciated as a feasible 
biomarker. Research efforts have investigated α-syn levels mainly in CSF and blood234, 235. 
CSF is directly reflecting processes in CNS but from a patient perspective and applicability to 
use in everyday clinic, a serum marker is preferable. In Paper IV, the first aim was to investigate 
if it is possible to detect amyloid aggregates in serum of PD patients using FCS. To detect 
structured aggregates exclusively, without interference from the non-toxic monomers present 
in excess, the fluorescent dye Thioflavin T (ThT) was used as it binds specifically to amyloid 
structures. The main findings are that the detected frequency of nanoamyloids (fSEO) is 
increased in PD patients compared to controls and preliminary data indicate that nanoamyloids 
in the patients and controls have a different size distribution (Fig. 15A).  
 
Since α-syn aggregation into amyloids is key in PD pathogenesis, the detected nanoplaques are 
potentially toxic aggregates, which have been organized into a structured β-sheet conformation. 
One of the strengths of the method is that it only detects structured amyloid aggregates without 
interference from the non-toxic monomeric α-syn. Since α-syn is extensively expressed in 
erythrocytes, variations in hemolysis easily affects total α-syn levels. This has been suggested 
to contribute to discrepancies between biomarker studies and has been drawback for blood-
based measurements235. Control experiments show that our method shows no increase of fSEO 
when applied to whole erythrocytes or lysed erythrocytes in plasma.  
A limitation is that ThT does not discriminate between different amyloid-structured proteins, 
reflected by the fact that also patients with Alzheimer’s disease (AD) have increased fSEO of 
nanoamyloids205. Hence, increased number of nanoplaques might be a sign of proteinopathy. 
Figure 15. fSEO of nanoamyloids is increased in PD patients A) Serum samples from PD patients have a 
higher frequency of detected ThT-positive nanoplaques compared to healthy controls. B) Average temporal 
autocorrelation curves for each group. C) Characteristic decay times for each group representing distinct sizes 
of nanoamyloids revealed by MEMFCS.  
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A large proportion of PD patients exhibit, in addition to Lewy bodies (LB), AD-like pathology 
upon neuropathological examination236, 237. Mechanistically, there is extensive data suggesting 
toxic association between -syn and amyloid-, the protein linked to AD238, 239. Methods 
detecting protein aggregates, such as the nanoaggregates, have therefore been suggested to be 
clinically relevant to demonstrate the common pathogenesis108.  
In addition to measuring the frequency of encountering the structured nanoaggregates (fSEO), 
the ThT-based FCS method enables simultaneous examination of the aggregates’ size 
distribution. In the data set analyzed in Paper IV, the MEMFCS analysis suggests that there are 
differences in aggregate size distribution between PD and controls (Fig. 15C). In particular, the 
fraction of smaller aggregates seems to be enriched in PD, which is in contrast to data for AD 
patients205. The size distribution of the ThT-responsive nanoaggregates may therefore be a 
specific disease-related biomarker.  
While the study in Paper IV provides a proof of principle, there are several important issues to 
be further investigated before the method can be considered for clinical use. Most notably, the 
number of individuals included in the study is very low and the results therefore needs to be 
replicated in a larger cohort. Of special importance is to understand if the measured bimodal 
size distribution is a characteristic for PD patients. If so, it should be possible to find a better 
clinical biomarker than the present fSEO, which does not correspond directly to nanoaggregate 
concentration due to the difference in diffusion speed between large and small aggregates. With 
known size distributions the fSEO could be directly correlated to concentration, which is 
preferable to a clinician. Finally the statistical power needs to be improved, either by 
prolonging the data acquisition time, or by increasing the sampling volumes, as in in massively 
paralleled FCS240, as the number of detected amyloids per individual are few. 
A quantitative biomarker can aid in several clinical situations. Detecting a disease is the most 
common application but indication of progression and treatment response is valuable 
information, especially in pharmacological studies. The first aim of Paper IV was to determine 
if PD patients had an increased number of detected amyloid formed protein in serum, which 
we concluded and the result is discussed above. However, while recruiting patients to studies 
there are several factors to acknowledge. The clinical diagnosis of PD is in 25% of the cases 
not consistent with the neuropathological confirmed diagnosis82, 241 Apart from retrospective 
studies using neuropathological confirmed cases, this is a methodological issue for all clinical 
studies. In order to only include genuine PD and not atypical parkinsonism all cases diagnosed 
in less than 5 years were evaluated according to the MDS criteria for PD as those are designed 
to use in research settings74. Only patients fulfilling “clinically established PD” were included. 
Furthermore, included patients were regularly examined at an academic center focused on 
movement disorders, previously reported to increase accuracy of correct parkinsonian 
diagnosis242. There is a large difference in age between patients and controls in the study. Even 
if we, to date, have no data suggesting a correlation between age and nanoaggregates, this is a 
potential bias. There is a decline in the proteostatis network with age and loss of proteostasis 
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has even been suggested as a hallmark of aging why this should be taken into consideration117, 
243.  
The second aim of the study was to evaluate the applicability of this biomarker to mirror disease 
progression or severity. The frequency of detected amyloid plaques (fSEO) were therefore 
correlated to clinical data and symptom scores. Unfortunately, just like previous effort for PD 
biomarkers, there was no correlation with age of onset, disease duration or H&Y stage, 
representing disease severity (Fig. 16). There can be a number of reasons for this apparent 
divergence. First, the sample size is small and the disease is highly heterogeneous possibly 
requiring larger cohort to find correlations. Second, this biomarker might detect a subset of PD 
patients with more pronounced protein aggregation disturbances. Finally, there is poor 
correlation even between symptom severity and α-syn load in the brain195, 244. This reveals that 
the apparent connection between LB load and disease is more complex and likely a reason why 
we, to date, do not have any peripheral biomarker for progression in clinical use. 
 
Both motor- and non-motor symptoms (NMS) were correlated to the fSEO of nanoplaques. 
Motor symptoms, evaluated by UPDRS III, did not correlate with detected frequency of 
nanoplaques (Fig. 17A). UPDRS III varies with treatment response and time since medication. 
In theory, this could easily be standardized. However, for severely diseased patients it is 
challenging, if not impossible, to come to an appointment without medication. Since we aimed 
to determine if the nanoplaques correlated with disease progression, we needed to include also 
the most severely affected patients who require regular medication. Apart from a significant, 
 Patients Controls p= 
Age (years) 73,8±8,6 46,5±11,4 <0,001 
Gender (M:F) 1:1 1:1 1 
Age of onset (years) 64,6±8,2 NA  
Disease duration (years) 8,1±5,2 NA  
MDS-UPDRS 56,8±29,4 NA  
UPDRS III 28,7±16,1 NA  
MoCa 23,9±6,1 NA  
MADRS-S 10,2±5,6 NA  
Table 1. Demographic data of patients presented in Paper IV. 
Figure 16 fSEO does not correlate with disease severity or progression. No correlation between age of 





however, weak inverse correlation with depression depth score we could not detect correlation 
with other NMS examined (Fig. 17B and C). The very weak inverse correlation with MADRS-
S score needs to be replicated in a larger study including subgroup analysis with treatment 
included as a variable before any conclusion can be made.  
 
In summary, the study concludes an increased number detected nanoplaques in PD compared 
to controls but the correlation to clinical measures remains to be determined. As is evident from 
the introduction of the Thesis, there are a number of pathological mechanisms contributing to 
PD development. Most likely, different mechanisms have various impact on disease progress 
in each individual. Also in the small cohort in Paper IV, there is a large inter-individual 
variation in the fSEO of nanoaggregates. Potentially, increased nanoaggregates reflect the 
subgroup of PD patients with major dysfunction in protein aggregation and/or protein 
degradation system. To increase diagnostic precision, multiple biomarkers reflecting different 
pathological events might be needed where the nanoamyloids possibly can be one of them. To 
validate this, the method needs to be applied to an increased sample size and long-term follow 




Figure 17. Correlation examination of fSEO with symptoms of PD. A) No correlation between motor 
symptom score and fSEO. B) A slight inverse correlation (r2=0,19, p=0,046) between depression depth and 
fSEO but as evident from the plot only accounts for a small part of the variability within the patient group and 
needs further validation. C) No correlation between cognitive decline determined by MoCa score and fSEO. 
All data set are evaluated by linear regression.  
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5 CONCLUSIONS AND OUTLOOK 
Moving from molecular understanding to explanations of human physiology is complicated. 
This Thesis investigates, in a translational attempt, a number of molecular interaction between 
proteins linked to PD to elucidate physiological function, sign of disease, and possible 
pharmacological interventions. We report functional connectivity between GPR37 with a 
proposed ligand, PSAP, the lipid GM1 and the receptor D2R and try to elucidate functional 
outcomes of each interaction. The heterodimerization between GPR37 and D2R is affected by 
pramipexole and is therefore of direct clinical relevance. GPR37 partitions with endogenous 
GM1-enriched lipid rafts, common for GPCRs. In addition, exogenous GM1 elicit 
cytoprotection via a GPR37-dependent mechanism. Finally, we describe increased detection of 
nanoamyloids in serum from PD patients, a potential molecular sign of disease. This paper 
reflects how methods, usually only applied in preclinical research, has potential improve 
clinical research investigations.  
To achieve translationally relevant results, the molecular conclusions of this Thesis needs to be 
extended from the simple systems to more complex. With the limitations that arise with cell 
lines as model systems future studies can hopefully use the results as one step towards clinical 
application. For the interaction studies, future experiments should include validation in primary 
systems and elucidate the physiological outcome of GPR37-D2R interaction in vivo. Since 
heterodimerization is reported to change with pramipexole treatment, both the physiological 
outcome as well as the molecular details of the interaction need to be explained further. Long 
term, this can potentially help in designing more specific dopamine agonists with less side-
effects, a daily clinical issue. Furthermore, it should be deciphered if GM1’s role on GPR37 
function is via direct interaction or changes in membrane composition. However, more 
important is to confirm the cytoprotective mechanism in vivo since the translation of GM1 from 
experimental treatment into clinical standard care has been hampered. Future studies regarding 
the nanoamyloids in PD patients would benefit from molecular characterization of the 
nanoplaques and hence, should move in the opposite direction from complex to simple. 
Characterization of the proteins in the nanoplaques is needed to identify the biological signal 
which might give us a hint of the cellular pathological events. Translational medicine is usually 




6 SUMMARY OF PAPERS 
This Thesis is based on the four papers listed below. The papers are related to molecular 
interactions in the dopaminergic system and specifically related to Parkinson’s disease. Paper 
I-III include biomolecular studies to elucidate the function of GPR37. In Paper I and II, GPR37 
is studied using FCS and FCCS in live cells. FCS is then applied in Paper IV to investigate 
nanoamyloids in serum from PD patients. The author has been main responsible for Paper II 
and III including study design, preparation and execution of experiments, analyzing data and 
writing the papers. Modeling of GPR37 in Paper III was done by M. Saarinen who also 
optimized the HTRF assay. In Paper I, the author did revision experiments regarding free PSAP 
levels after immunoabsorption, analyzed the data and edited the manuscript thereafter. The 
other results including the FCS measurements were done by the first author, E. Gregorsson 
Lundius. Regarding Paper IV, the main responsibility is shared. The author planned and 
executed the clinical evaluations, analyzed the data for correlations and wrote the paper. The 
FCS experiments and analysis were done by A. Tiiman.  
Paper I: GPR37 Protein Trafficking to the Plasma Membrane Regulated by Prosaposin 
and GM1 Gangliosides Promotes Cell Viability.  
This paper investigates factors affecting GPR37 trafficking which in turn affects N2a cell 
viability. Using FCCS, GPR37 is shown to form a complex with both PSAP and GM1. PSAP 
immunoabsorption reduced GPR37 localization at the plasma membrane, reduced 
colocalization with GM1, and decreased cell viability, both in WT and GPR37-overexpressing 
cells.  
Paper II: GPR37 and GPR37L1 Differently Interact With Dopamine 2 Receptors in Live 
Cells 
This paper studies the interaction between GPR37 and splice variants of D2R and compare the 
results with GPR37L1, using FCCS. At baseline conditions, GPR37 and D2RL show higher 
complex-formation than GPR37 and D2RS. The level of complex formation can be increased 
by treating cells with a dopamine agonist or a chemical chaperone increasing GPR37 
expression at the plasma membrane. GPR37L1, on the other hand, show higher complex 
formation with D2RS than D2RL. The level of complex formation is very low, cannot be 
increased with treatments as above and is hence difficult to distinguish with certainty from 
background noise.  
Paper III: GM1 is Cytoprotective in GPR37-expressing Cells and Downregulates 
Signaling 
This paper investigates the functional effects of the interaction between GM1 and GPR37 
detected in Paper I. GPR37-overexpressing N2a cells express decreased levels of GM1 and are 
specifically rescued with exogenous GM1 in a toxin-induced cellular model. GM1 treatment 
directly inhibit GPR37-induced decreased cAMP levels in HEK cells, suggesting a hypothesis 




Paper IV: Increased Amyloid Nanoplaques in Serum from Patients with Parkinson’s 
Disease. 
This paper evaluates ThT-positive nanoamyloids in serum from patients with PD and controls 
as a biomarker for PD. The nanoaggregates are investigated both as a marker for disease as 
well as in correlation with clinical parameters and symptoms to measure disease progression. 
We detect increased number of nanoaggregates in PD patients compared to controls and the 
size of the aggregates are partly different, both from controls and AD patients. There is 
presently no correlation with demographic data, progression or motor symptoms. The weak 
inverse correlation between depression symptoms and number of nanoaggregates reported 
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